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Designing Rational Combination Strategies for Overcoming 
Drug Resistance in Breast Cancer 
 
Hayley Jeton Donnella 
Abstract 
 
Drug resistance is a ubiquitous problem in the therapeutic management of breast cancer, even in 
the context of next-generation targeted therapies where only modest clinical improvements have 
been observed despite a tumors mutational load for a given target pathway or intrinsic subtype. 
To devise effective anti-cancer treatment strategies, new systems-based methods are needed to 
fully interpret factors underlying drug responses encompassing both genetic and non-genetic 
mechanisms. Here we developed two approaches towards designing novel combination strategies 
for overcoming drug resistance. First, using an unbiased chemoproteomics approach, we profiled 
kinome dynamics across breast cancer cells in response to various targeted therapies and 
identified signaling changes that correlate with drug sensitivity. This signaling map identified 
survival factors whose presence limits the efficacy of targeted therapies and revealed AURKA as a 
new co-targeting opportunity to enhance the therapeutic efficacy of PI3K-pathway inhibitors in 
breast cancer. Second, we used single-cell transcriptomics data and pharmacogenomic modeling 
as a way to inform upfront drug combinations based on systematic analysis of tumor 
subpopulation architectures.  Using in silico and experimental approaches, our study provides an 
effective new framework to discover drug combinations capable of counteracting intrinsic cell 
	 ix 
variability by predicting drug responses of single cells within tumor cell subpopulations and 
systematically links transcriptional heterogeneity with drug actionability to optimize therapy 
combinations. 
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Chapter 1.  
Introduction 
 
1.1 Breast cancer landscape and treatment options 
 
Breast cancer remains a highly prevalent disease with 1 in 8 women developing invasive breast 
cancer during her lifetime. This presents as the most common cancer among women in the 
United States, accounting for over 15% of all newly diagnosed cancers, with a predicted 258,600 
new cases and 41,670 breast cancer patient deaths in 20191. Breast cancers are typically 
diagnosed based on the presence/absence of receptor expression into receptor-positive (estrogen 
receptor, ER; progesterone receptor, PR), ErbB2 (HER2)-amplified or triple-negative breast 
cancer (TNBC) indications, and treatment options vary depending on disease stage at 
presentation and tumor subtype. However, as a result of inter-tumoral heterogeneity (between 
patient variability in tumor phenotype), improvements in the clinical management of this disease 
have not been equal across all patient groups. In breast cancer, the discovery of biomarkers has 
now led to classifying tumors based on gene expression patterns into five molecular subtypes 
including Luminal A/B, HER2-enriched, and two triple-negative subtypes, Basal-like and 
Claudin-low2–4. Molecular variability between individual cancer patients can predict who will 
respond to treatment, such as differences in molecular subtypes, which is crucial in determining 
predicted responsiveness to standard-of-care therapies5–7. Accordingly, classification of intrinsic 
molecular subtype from bulk patient tumor samples has become an important diagnostic tool to 
	 2 
predict risk of relapse and response to chemotherapy in breast cancers. However, patients do not 
present with homogenous tumors clinically, often times lacking uniform expression of 
therapeutic targets8. This heterogeneity can severely impact the clinical assessment of a tumor 
and subsequent therapeutic regimens, and may facilitate recurrence whereby subpopulations of 
cells are spared during treatment. Furthermore, several preclinical and clinical observations have 
shown that genotype alone fails to predict drug response9–12, suggesting that therapeutic efficacy 
is often based on the presence of molecular modifiers not represented by global measures of 
subtype and receptor diversity.   
 
 
1.2 Therapeutic targeting of driver kinases in breast cancer 
 
As our understanding of the molecular biology of cancer has advanced, drug development has 
shifted towards agents that target specific molecular alterations in tumors. Exome sequencing has 
revealed that frequent mutation in genes of the PI3K/AKT/mTOR pathway is a prominent 
feature of breast cancers. Genomic alterations of PI3K-pathway components, including PTEN, 
PIK3CA, and AKT1, occur in over 60% of breast malignancies13. Accordingly, inhibition of this 
signaling pathway is an attractive avenue of investigation for therapeutic intervention and has led 
to the advancement of more than 30 inhibitors currently in clinical development that target the 
PI3K/AKT/mTOR machinery in breast and other cancers14–18. Despite this being one of the 
most active areas of drug development, multiple clinical trials demonstrate that monotherapy 
responses to these inhibitors remain modest. Collectively, there was merely an 18% response rate 
	 3 
in patients harboring PIK3CA mutations or PTEN aberrations and a minimal 1.8 month 
improvement of progression free survival (PFS) when treated with single-agent 
PI3K/AKT/mTOR inhibitors19. It is therefore likely that new approaches to identifying 
efficacious treatment regimens are necessary in order to improve clinical outcomes. 
 
 
1.3 Factors underlying drug resistance and response to targeted 
therapies in breast cancer 
 
Drug resistance is a major problem in breast cancer where insensitivity to chemotherapy is 
associated with a 40 to 80% risk of recurrence after neo-adjuvant therapy resulting in incurable 
metastatic disease and death for most patients20–22. The need for new therapeutic approaches is 
particularly pressing in the context of triple-negative breast cancers (TNBC) where responses to 
chemotherapy are often not durable. In the case of neo-adjuvant chemotherapy, 30 to 50% of 
patients with localized TNBC evolve resistance leading to poor overall survival for this group of 
patients23,24. The ubiquity of drug resistance in breast cancer remains a problem even in the 
context of next-generation targeted therapies where only modest improvements in PFS and 
overall survival (OS) have been observed despite a tumors mutational load for a given target 
pathway or intrinsic subtype11,12,19,25,26. As such, new approaches are needed to fully interpret 
factors underlying drug responses in breast cancer encompassing both genetic and non-genetic 
mechanisms.  
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1.3.1 The kinome resiliency conundrum and adaptations to targeted therapies  
The clinical observation that tumors with mutations in the PI3K/AKT/mTOR pathway fail to 
respond to therapy suggests that additional factors modulate cellular response and drive 
resistance to PI3K-pathway inhibition. Such factors include (1) drug-induced changes in 
feedback signaling resulting in pathway reactivation, and (2) compensatory activation of parallel 
signaling networks capable of transmitting new oncogenic signals (Fig. 1.1). Within the 
PI3K/AKT/mTOR signaling network, numerous drug-induced feedback adaptations are now 
defined. For example, treatment of PI3K-hyperactivated cells with an allosteric mTORC1 
inhibitor induces upstream receptor tyrosine kinase (RTK) signaling resulting in increased AKT 
activation27,28. mTORC1 inhibition is also known to directly induce PI3K signaling by relieving 
GRB10-mediated suppression29,30. Similarly, AKT inhibition (and direct inhibitors of PI3K to 
the extent that they result in AKT inhibition) induces the RNA expression of RTKs, thus 
relieving feedback suppression of RTK activity31,32. These data indicate drug-induced reliefs of 
feedback result in reactivation of the PI3K/AKT/mTOR pathway, effectively rendering drugs 
directed towards this pathway less potent. An alternate means of targeted therapy resistance is 
drug-induced compensatory activation of alternate signaling pathways (2). The PI3K and 
RAS/RAF/MEK/ERK networks interact at multiple levels; several groups have shown 
inhibition of PI3K signaling nodes results in MAPK pathway activation and vice versa31,33–37. 
These studies collectively highlight the emergence of drug-induced resistance and underscore the 
importance of redundancy and feedback within signaling networks. 
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Discovery of factors underlying drug-induced feedback phenomena has guided the development 
of current combination therapies focused on pursuing specific downstream effectors of the target 
pathway, or components of compensatory pathways as companion targets. In the context of 
breast cancer, multiple efforts in the field have identified mTORC1 as a survival factor whose 
suppression is necessary for PI3K-pwaty inhibitor sensitivity38,39. This observation has led to 
multiple clinical trials directed towards using drug combinations with PI3K/AKT/mTOR 
inhibitors, yet reported results have yielded suboptimal outcomes due to increased systemic 
toxicity and cytostatic tumor effects40. Hence, there remains a pressing need to uncover routes of 
resistance and combination targets that have not yet been explored in order to improve 
therapeutic efficiency. As such, identifying additional survival factors requires a comprehensive 
understanding of signaling dynamics in response to treatment and insight as to how these 
dynamics contribute to drug resistance. 
 
1.3.2 Profiling kinome activation dynamics using Multiplexed Inhibitor Beads 
(MIBs)  
To do so, we need an unbiased approach to monitor dynamic signaling responses following 
targeted kinase inhibition. Initial efforts in kinome adaptation studies made use of kinase activity 
assays, immunoblotting for select kinases and their active forms, or large-scale 
phosphoproteomic analyses41,42. However, these studies are limited due to reagent availability and 
specificity, and the complexity of the phosphoproteome without preference for kinases. To 
address this, kinase enrichment strategies using chemoproteomic techniques that combine kinase 
affinity capture with quantitative mass spectrometry (MS) have emerged. Investigators used 
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immobilized Type I kinase inhibitors coupled to Sepharose beads to target the ATP-binding 
pocket43–45 (Fig. 1.2a). This allows for unbiased capture of endogenous kinases based on activity 
state and abundance. Recently, a derivation of this approach showed that capture of expressed 
kinases can be improved by multiplexing a set of immobilized pan-kinase inhibitor beads (MIBs) 
onto a modular affinity column46–48. MIB-bound kinases can then be identified by off-line LC 
separation and quantitative MS, providing a systems-wide approach to profile kinome activity 
(Fig. 1.2b,c). 
 
1.3.3 Rare tumor subpopulations and heterogeneity at the single-cell transcript 
level  
Another source of drug resistance in breast cancer can be attributed to the presence of intra-
tumoral heterogeneity and rare subpopulations of cells having differential impacts on overall 
response (Fig. 1.3). Pre-existing genetically diverse subclones within a tumor mass can harbor 
resistance-conferring mutations resulting in eventual clonal expansion following a Darwinian 
selection of distinct cell subpopulations after an initial response to therapy. However, clinical 
evidence from breast cancers undergoing neo-adjuvant chemotherapy have indicated treatment 
often does not result in subclonal selection demonstrating that it is not necessarily genetically 
encoded49–52. In the absence of pre-existing subclones, subpopulations of cells can undergo a 
drug-induced adaptation towards a drug-tolerant state where cells can persist over the course of 
treatment and eventually acquire a variety of possible resistance mechanisms including secondary 
mutations. Alternatively, rare subpopulations of cells in different cellular states can be pre-
existing prior to therapy and harbor differential drug sensitivities leading to distinct 
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subpopulations achieving therapeutic escape. Hence new approaches are needed to counteract 
both genetic and non-genetic factors contributing to drug resistance in breast cancer.    
 
1.3.4 Single-cell approaches for characterizing heterogeneity in breast cancer  
Single-cell DNA- and RNA-sequencing methods have emerged as powerful tools for resolving 
intra-tumoral heterogeneity, reconstructing tumor evolutionary lineages, and characterizing 
distinct tumor cell subpopulations in breast cancers49,53,54. However, approaches to use these data 
derived from single-cell studies towards predicting and testing new therapeutic strategies have 
remained a challenge. Studies linking genomics to drug efficacy, or pharmacogenomics, have 
relied on the analysis of large panels of cell lines or PDX systems having been both molecularly 
profiled and functionally challenged through high-throughput drug screens. However, these bulk 
assays have limited application to studying the functional consequences of cell-cell variability in 
that heterogeneous responses of cells from within a bulk population and subtle changes in cell 
state or gene expression are obscured in bulk analysis. Therefore, the functional implications that 
individual cells within a population pose on therapeutic responses remains unknown due to the 
lack in feasibility of directly challenging a single live cell with drug. As such, approaches for 
characterizing genetic and functional variability contributing to drug response at the cellular level 
are needed to inform upfront drug combinations that elicit more complete anti-tumor responses. 
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1.4 Overarching project goals 
 
To date, there remain no gold-standard methods for designing rational combination strategies 
capable of combating drug resistance in breast cancer. This body of work seeks to address this 
challenge in a two-pronged approach studying various non-genetic factors contributing to drug 
response.  
 
(1) As detailed in Chapter 2, our first project centered on the concept of kinome signaling 
and pathway dynamics altering drug response. The guiding hypothesis of this research is 
that intrinsic resistance mechanisms for PI3K-directed therapeutics might coalesce on a 
distinct set of critical effector nodes. Mapping patterns of kinome behavior globally 
provides valuable, unbiased insights into the mechanistic implications of cell cycle and 
response to PI3K-pathway targeted agents. This method of analysis may provide a more 
precise model of cell signaling responses, enabling the accurate prediction of viable targets 
and thus constitutes a novel, translatable approach to developing rational therapeutic 
combinations for breast cancer treatment. In this study we developed a kinome-profiling 
technique to map signaling changes in response to various target therapies across subtypes 
and identified AURKA as a new co-targeting opportunity to enhance the therapeutic 
efficacy of PI3K-pathway inhibitors in breast cancer.  
 
(2) As detailed in Chapter 3, the second project in this body of work involved delineating the 
impact of transcriptional tumor cell heterogeneity on treatment response. We 
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hypothesized that non-genetic differences in cellular states between individual cancer 
cells may also reflect altered drug sensitivities and as such, can be used to inform upfront 
drug combinations that elicit more complete anti-tumor responses. Through 
pharmacogenomic modeling based on bulk cancer cell line drug sensitivities, we 
developed a new approach using a Modular Drug Response Prediction Pipeline 
(MODRx) in order to systematically discover drug combinations capable of counteracting 
tumor heterogeneity by predicting drug responses of individual breast cancer cells. Using 
in silico and experimental approaches, our study provides an effective new framework to 
discover drug combinations capable of counteracting intrinsic cell variability by predicting 
drug responses of tumor cell subpopulations and systematically links transcriptional 
heterogeneity with drug actionability to optimize therapy combinations. 
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1.5 Figures 
 
 
Figure 1.1 Kinome resiliency and adaptations mechanisms. Schematic detailing signaling 
dynamics in response to treatment with targeted therapies for a drug-sensitive tumor (left) and 
drug-resistant tumor setting (right). Signaling network crosstalk and redundancies can lead to 
drug-induced adaptations including reactivation of the target pathway and compensatory 
activation of alternate, parallel pathways.  
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Figure 1.2 Measuring kinome activation dynamics using Multiplexed Inhibitor Beads (MIBs) 
technology. (a) Type I kinase inhibitors (ATP-analogs) immobilized onto beads can be used to 
immunoprecipitate active kinases through binding of their ATP-binding pocket providing an 
unbiased way to capture endogenous kinases based on activity state and abundance. (b) 
Multiplexing a panel of immobilized-inhibitor beads onto an affinity column allows for broad 
coverage of the kinome. Eluted kinases are then identified by LC-MS/MS to generate kinome 
activity profiles. (c) MIBs/MS can be used to generate activity profiles across several different cell 
types or sample conditions providing a useful tool to characterize kinome dynamics.   
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Figure 1.3 Rare tumor subpopulations and heterogeneity at the single-cell transcript level.  
Figure adapted from Oxnard, GR.55 doi: 10.1038/nm.4058. (a) Pre-existing genetic subclones 
within a tumor mass can harbor resistance-conferring mutations resulting in eventual clonal 
expansion after an initial response to targeted therapy. (b) Targeted therapy treatment induces a 
durable drug-tolerant state where cells can persist over the course of treatment and eventually 
acquire a variety of possible resistance mechanisms including secondary mutations. (c) 
Alternatively, rare subpopulations of cells in different cellular states can be pre-existing prior to 
therapy and harbor differential drug sensitivities leading to distinct subpopulations achieving 
therapeutic escape.    
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Chapter 2.  
Kinome rewiring reveals AURKA limits PI3K-pathway 
inhibitor efficacy in breast cancer 
 
2.1 Abstract 
 
Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast 
cancers. However, clinical responses to drugs targeting this pathway have been modest, possibly 
because of dynamic changes in cellular signaling that drive resistance and limit drug efficacy. 
Using a quantitative chemoproteomics approach, we mapped kinome dynamics in response to 
inhibitors of this pathway and identified signaling changes that correlate with drug sensitivity. 
Maintenance of AURKA after drug treatment was associated with resistance in breast cancer 
models. Incomplete inhibition of AURKA was a common source of therapy failure, and 
combinations of PI3K, AKT or mTOR inhibitors with the AURKA inhibitor MLN8237 were 
highly synergistic and durably suppressed mTOR signaling, resulting in apoptosis and tumor 
regression in vivo. This signaling map identifies survival factors whose presence limits the 
efficacy of targeted therapies and reveals new drug combinations that may unlock the full 
potential of PI3K–AKT–mTOR pathway inhibitors in breast cancer. 
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2.2 Introduction  
 
Mutations and aberrant signaling of the PI3K–AKT–mTOR pathway (PI3K pathway) is a 
prominent feature of breast cancer and many other cancer types. Genomic alterations of PI3K-
pathway components including PTEN, PIK3CA and AKT1 occur in over 60% of breast 
malignancies1. Despite this high prevalence, drugs targeting this pathway have demonstrated 
only modest responses across numerous clinical trials2,3. The clinical observation that most breast 
cancers fail to respond suggests that additional factors modulate cellular response and drive 
resistance. A prominent feature of this pathway is drug-induced signaling adaptation and 
feedback mechanisms resulting in suboptimal drug responses4–6. Therefore, it is likely that 
understanding and targeting these dynamic changes in signaling will be important for optimizing 
this class of agents. 
 
In principle, the measurement of dynamic changes elicited by therapy can be used to develop 
novel drug combinations. Though previous efforts have focused on acute signaling changes 
leading to pathway reactivation and drug resistance4,7, a systematic comparison of global 
signaling changes with drug efficacy has not been performed. Such an analysis may reveal 
survival factors whose suppression is required for drug efficacy, and hence could reveal new 
combinatorial strategies to enhance therapeutic responses. Previous identification of such factors 
has led to the understanding that drug-induced activation of apoptotic machinery8,9 and 
impairment of protein synthesis10 is required for sensitivity to a wide variety of drugs. In the 
context of breast cancer, multiple efforts in the field have identified mTORC1 as a survival factor 
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whose suppression is necessary for PI3K-pathway inhibitor sensitivity11,12. This observation has 
led to clinical trials combining PI3K and mTOR inhibitors, yet reported clinical results have 
yielded suboptimal outcomes as a result of increased systemic toxicity and cytostatic tumor 
effects3. Hence, there remains a pressing need to uncover new combination targets in order to 
improve therapeutic efficiency of PI3K-pathway inhibitors. Identifying additional survival factors 
will require a comprehensive understanding of signaling dynamics in response to treatment and 
insight as to how these dynamics contribute to drug resistance. 
 
Little is known about global kinome rewiring in response to drug treatment, due in part to 
limitations in available technologies. Recently, a kinase-enrichment strategy has been developed 
using a chemoproteomics technique that combines kinase affinity capture with quantitative mass 
spectrometry (MS). This approach uses a multiplexed set of type I kinase inhibitors immobilized 
onto beads (multiplexed inhibitor beads, MIBs), which are used to affinity purify a diverse set of 
active kinases through their increased avidity for ATP compared to inactive kinases. Enriched 
kinases are then identified and quantified by LC–MS/MS (MIBs/MS), enabling simultaneous 
measurement of many endogenous kinases based on their activity state and abundance7. Because 
many drugs impinge on common pathways, and cell lines often display unique behaviors, it is 
possible that a quantitative map of kinase dynamics spanning multiple cell lines and drug 
treatments may be used to identify more general responses to drug treatment that are linked to 
drug sensitivity. 
 
Here we applied the MIBs/MS approach to identify signaling changes associated with drug 
efficacy by mapping the kinome following exposure to targeted therapies across a panel of breast 
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cancer cell lines of various subtypes and genotypes. Comparison of kinome activity profiles 
between drug-sensitive and resistant cells allowed us to generate a kinome-response signature 
associated with drug sensitivity. By performing a systematic analysis of signaling dynamics 
following drug treatment, we identified that failure to inhibit AURKA was associated with 
resistance to a diverse set of targeted therapies. Further analysis revealed that inhibition of 
AURKA was sufficient to engender strong synergistic responses when combined with inhibitors 
of PI3K, AKT or mTOR. This provides an effective new framework for the unbiased 
identification of survival factors acting as molecular barriers to the efficacy of drugs, and we 
demonstrate the utility of this approach by developing rational combination strategies to enhance 
responses to PI3K-pathway inhibitors in breast cancer. 
 
 
2.3 Results  
 
2.3.1 Generation and analysis of a dynamic kinome signaling map  
We applied an unbiased proteomic strategy to measure kinome rewiring in response to drug 
treatment. Kinome profiling was performed via a chemoproteomics approach using MIBs 
coupled with mass spectrometry (MIBs/MS). Our library of MIBs consists of a mixture of 
sepharose beads covalently linked to 12 kinase inhibitors ranging from moderately selective (for 
example, lapatinib or sorafenib) to pan-kinase inhibitors (for example, purvalanol B or 
staurosporine) for broad kinome coverage (Fig. 2.1a; Supplementary Fig. 2.1). Because type I 
kinase inhibitors preferentially bind kinases in their active conformation, kinase capture by MIBs 
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under the stringent binding conditions used here is a function of kinase expression, the affinity of 
kinases for the immobilized inhibitors, and the activation state of the kinase13. DMSO or drug-
treated cell lysates were incubated with MIBs, and enriched kinases were eluted and quantified 
by LC–MS/MS using label-free quantitation (see Methods)14. We estimate that our current 
approach is able to capture roughly 35% of highly expressed kinases in a given sample 
(Supplementary Fig. 2.2). 
 
We applied this strategy to a panel of breast cancer cell lines of various subtype and genotype 
classifications and measured kinome dynamics following treatment with a panel of targeted 
therapies. Cell lines were chosen to maximize transcriptional diversity and span the major 
subtypes of breast cancer (Supplementary Fig. 2.3). All lines harbored mutations in PI3K-
pathway genes including PIK3CA mutant MCF7 (ER+/PR+), BT20 (receptor negative) and 
T47D (ER+/PR+); PTEN-null BT549 (receptor negative); and HER2-amplified SKBR3 
(HER2+) (Supplementary Fig. 2.4a). Cell lines were treated for 24 h with DMSO or kinase 
inhibitors relevant to breast cancer signaling, including the EGFR/HER2 inhibitor lapatinib 
(200 nM), the pan-class I PI3K inhibitor GDC-0941 (250 nM), the AKT inhibitor MK2206 
(250 nM), and the MEK inhibitor PD0325901 (100 nM), and then profiled using MIBs/MS 
(Fig. 2.1a; Supplementary Fig. 2.4b). Together, we quantified changes across 151 kinases in 
total, with changes in 75 kinases present in over 75% (15/20) of the samples (Fig. 2.1b; 
Supplementary Dataset 2.1). Significant drug-induced changes (defined based on the log2 fold 
change of drug versus DMSO treatment, logFC) were detected for 99 kinases at P < 0.001, 
corresponding to 66% of kinases measured, indicating that the drugs had widespread and 
significant impacts on global kinome dynamics. 
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To assess the quality and reproducibility of the MIBs/MS data, we initially compared biological 
replicates of SKBR3 (HER2+) cells treated with the dual EGFR/HER2 small-molecule inhibitor 
lapatinib. We observed a high correlation of 0.78 between replicates for identified kinases (P = 5 
× 10−26) (Fig. 2.1c). The MIBs/MS screening strategy also accurately captured activity inhibition 
of direct drug targets by lapatinib, indicated by the significant decrease in levels for EGFR 
(logFC = −5.8, P = 6 × 10−5) and HER2 (−0.7, P = 1 × 10−4) (Fig. 2.1c). We observed a decrease in 
MEK1 activity upon treatment with the MEK inhibitor PD0325901 in BT549 and MCF7 cells 
(logFC = −1.8 and −1.2, respectively; Fig. 2.1d). We also observed indirect pathway-specific 
events, such as a decrease in the activity of the mTOR effector kinase RPS6KB1 when treated 
with either the PI3K inhibitor GDC-0941 or the AKT inhibitor MK2206 in MCF7 cells 
(logFC = −3.5 and −2.3, respectively; Fig. 2.1e). Comparison of observed kinome changes to 
previous MIBs/MS data revealed a high degree of concordance (Supplementary Fig. 2.5)15. 
These results highlight the reproducibility of the MIBs/MS approach, as well as its ability to 
identify direct and indirect drug targets based on reductions in both activity and abundance. 
 
We hypothesized that the identification of shared responses across lines and drugs may lead to a 
more robust understanding of signaling dynamics, as opposed to changes specific to a particular 
drug or cell type. We therefore sought to identify changes that were generally associated with 
sensitivity or resistance to treatment in a drug-agnostic fashion. First, cell lines were classified as 
sensitive or resistant to each of the drugs in our panel on the basis of dose–response analysis 
(Supplementary Fig. 2.4b; Supplementary Fig. 2.6a-d). Next, fold changes for each kinase were 
compared between these sensitive and resistant classifications for all drugs pooled together to 
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identify candidate kinases whose inhibition was associated with drug sensitivity (Fig. 2.1f). This 
analysis revealed that suppression of 12 kinases was significantly associated with drug sensitivity 
(P < 0.05). Among the identified candidates were kinases involved in cell-cycle processes, 
including mitotic kinases AURKA (P = 0.0001) and CDK1 (P = 0.04), and kinases involved in 
interphase, including CDK4 (P = 0.02) and CDK2 (P = 0.05). Other kinases identified were 
involved in YAP signaling (STK4, P = 0.01) and WNT signaling (GSK3B, P = 0.005 and 
CSNK1E, P = 0.02). These results were not linked to general impairment of the cell cycle per se. 
We observed no correlation with sensitivity for other cyclin-dependent kinases (CDKs) 
measured in our screen such as CDK6, which is closely related to CDK4. In addition, the 
AURKA paralog AURKB was not significantly associated with sensitivity even though it is 
regulated during mitosis in a similar manner (Fig. 2.1f)16. We performed a similar analysis using 
a three-response categorization (i.e., sensitive, moderately sensitive and resistant) and found that 
these results were largely independent of the way sensitivity was classified (Supplementary 
Fig. 2.6e-g). We postulate that this drug-agnostic approach identifies changes that are general to 
drug sensitivity and reveals factors that may be missed by studies limited to a single-drug 
analyses. For example, the top candidate from our analysis, AURKA, was implicated but not 
found to be significantly associated with resistance or even among the top several candidates with 
any single drug. However, by pooling responses across all drugs it emerged as the one most 
associated with resistance in terms of both magnitude and significance (Supplementary Fig. 2.7). 
Therefore, by performing a systematic screen of signaling dynamics following drug exposure, we 
identified a set of specific kinases whose maintenance was associated with resistance to targeted 
therapies in breast cancer. 
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2.3.2 AURKA associates with PI3K and AKT inhibitor resistance  
We focused our validation of molecular correlates of drug sensitivity on the PI3K pathway 
because of its central importance to breast cancer. We observed a significant association between 
maintenance of AURKA after treatment and drug resistance (Fig. 2.2a). To confirm this result, 
we measured molecular responses to treatment with the pan-PI3K inhibitor GDC-0941 in two 
sensitive (T47D and MCF7, IC50 < 200 nM) and two new cell lines that were robustly resistant 
(HCC38 and MDAMB453, IC50 > 40 µM). A critical output of the PI3K pathway is the 
activation of the mTORC1 complex, whose inhibition is necessary for sensitivity to PI3K 
inhibitors11. After treatment we observed suppression of mTORC1 activity only in sensitive cells, 
as evidenced by decreased phosphorylation of its effector protein S6 (Fig. 2.2b). Confirming our 
MIBs/MS data, in response to treatment we observed decreases in the abundance and 
autophosphorylation of AURKA in sensitive cells, whereas resistant cells maintained these levels 
throughout (Fig. 2.2b; Supplementary Fig. 2.9a,b). Similar results were observed using the AKT 
inhibitor MK2206, representing the next step in the PI3K pathway (Supplementary Fig. 2.9c-e). 
These results confirm that failure to suppress AURKA activity is associated with resistance to 
PI3K and AKT inhibition in breast cancer cells. 
 
We next asked how AURKA is regulated in response to PI3K-pathway inhibition in drug-
sensitive cells. AURKA regulates centrosome alignment, mitotic-spindle formation and 
chromosome segregation during mitosis, and its activity and abundance is tightly regulated16. We 
observed a robust and significant change in AURKA protein levels after 24 h in drug-sensitive 
cells, leading us to hypothesize that changes in transcription of AURKA might account for its 
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loss after treatment. AURKA mRNA levels were decreased in response to GDC-0941 and 
MK2206 when comparing drug-sensitive and resistant cell lines (P = 2.8 × 10−5 and P = 0.004, 
respectively; Fig. 2.2c,d). In addition, transcriptomes of MCF7 and T47D cells treated with the 
PI3Kα-specific inhibitor BYL719 for 24 h17 reflected a significant reduction of AURKA after 
drug treatment in both of these BYL719-sensitive cell lines (IC50 ≤ 250 nM; Supplementary 
Fig. 2.10a)11,18. Interestingly, Gene Set Enrichment Analysis (GSEA)19 of these transcriptomes 
revealed that a prominent component of the response to PI3K inhibition was the suppression of 
genes involved in the G2/M checkpoint, including AURKA, suggesting that transcriptional 
control of this aspect of the cell cycle is a major output of the PI3K pathway (Fig. 2.2e; 
Supplementary Fig. 2.10b; Supplementary Dataset 2.2). 
 
2.3.3 AURKA mediates survival during PI3K-pathway inhibition 
We next asked if the downregulation of AURKA was functionally relevant and whether the 
presence of AURKA limits efficacy of PI3K-pathway directed therapies. We tested whether 
AURKA inhibition was sufficient to confer sensitivity to PI3K-pathway inhibitors using a 
combination-profiling approach to measure drug synergy across an extended panel of 13 breast 
cancer cell lines. We applied a dose matrix of increasing concentrations of the AURKA-specific 
inhibitor MLN8237 alone and in combination with a PI3K (GDC-0941), AKT (MK2206) or 
mTOR (RAD001) inhibitor and measured the effects on cell proliferation. To evaluate drug 
synergy, we (1) visualized Loewe excess values, (2) scored combination index values measuring 
shifts in drug potency, (3) calculated synergy scores based on Loewe excess values and (4) 
visualized and scored combinations using a Bliss independence model20 (see Methods). Our 
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results in MCF7 cells indicated that MLN8237 in combination with GDC-0941, MK2206 or 
RAD001 was synergistic using all four approaches (Fig. 2.3a; Supplementary Figs. 2.11 – 2.13; 
Supplementary Dataset 2.3). By testing the combination of MLN8237 with GDC-0941 across 
the extended panel of cell lines, we found significant synergy based on the Loewe excess model in 
38% of models (5/13) on the basis of a synergy score > 1, which we determined through 
simulation to represent a less than 5% chance of nonsynergy (i.e., FDR < 5%; Fig. 2.3b; 
Supplementary Fig. 2.11). We extended this analysis to drug combinations of MLN8237 with 
either MK2206 or RAD001 and found significant synergy in 54% and 85% of models, 
respectively (Fig. 2.3b; Supplementary Figs. 2.12 and 2.13). Overall, we found no significant 
trend toward synergy based on PIK3CA or PTEN mutational status, but did observe slightly 
increased synergy in receptor-positive cell lines (ER+ or HER2+ ; P = 0.04 for GDC-0941 
and P = 0.035 for MK2206, based on a two-tailed t-test; Supplementary Dataset 2.3). 
 
Because PI3K-pathway inhibitors are primarily cytostatic5,21 and AURKA is known to regulate 
apoptosis22, we next asked whether AURKA inhibition could enhance responses to PI3K-
pathway inhibitors by inducing cytotoxic responses. Across 12 cell lines, we found that the 
addition of MLN8237 caused an increase in apoptotic cell death (Fig. 2.3c) that was 
independent of the particular dose used (Supplementary Fig. 2.14a,b). This enhancement in cell 
death generally occurred in conditions in which synergy was also observed (Supplementary 
Fig. 2.14b). We compared this response with the combination of CDK4/6 and PI3K inhibitors 
which are known to be synergistic12. Although we observed synergy between PI3K, AKT and 
mTOR inhibitors and the CDK4/6 inhibitor LEE011, the response was primarily cytostatic, 
indicating that CDK4 and CDK6 are only necessary for proliferation rather than for tumor cell 
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survival in the presence of PI3K-pathway inhibitors (Supplementary Fig. 2.14c-e; Supplementary 
Dataset 2.3). Therefore, AURKA mediates cellular survival in the context of PI3K-pathway 
inhibition, and because the drug combinations are synergistic in inducing apoptosis in breast 
cancer cells, we propose that it may be a promising companion target to enhance the efficacy of 
PI3K-pathway inhibitors. 
 
2.3.4 MLN8237 and Everolimus (RAD001) induce cell death in vivo 
We next evaluated the efficacy of this combination in vivo and focused on the combination of 
MLN8237 with the only FDA-approved inhibitor targeting this pathway in breast cancer, the 
mTOR inhibitor RAD001 (everolimus). Clinically, RAD001 overwhelmingly results in disease 
stabilization rather than regression23. This is reflected in vitro, wherein all lines have a high 
RAD001 Emax, indicating cytostatic effects. In particular, MCF7 cells have a high Emax of 0.54 
and do not display evidence of poly(ADP-ribose) polymerase (PARP) cleavage at high doses 
(Supplementary Fig. 2.15). To investigate whether AURKA suppression enhances the response 
to RAD001 treatment, we tested the combination in MCF7 orthotopic transplants. Though 
RAD001 or MLN8237 monotherapy only partially impaired tumor growth, the combination 
showed significantly greater tumor growth inhibition than either single agent alone (Fig. 2.4a). 
Furthermore, all animals receiving the combination therapy (9/9) showed marked tumor 
regression, whereas no regressions were observed with monotherapy (0/13 in total; P = 2 × 
10−6 by Fisher’s exact test; Fig. 2.4b). Post-treatment tumor specimens displayed an induction of 
apoptosis specific to the combination, as demonstrated by an increase in the number of 
TUNEL-positive cells (Fig. 2.4c,d). During the course of study, we did not observe any 
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significant weight loss in animals receiving the combination as compared to the RAD001 single-
agent group (Supplementary Fig. 2.16), suggesting tolerability and a lack of added toxicity from 
co-inhibiting Aurora kinase A. Therefore, addition of MLN8237 to RAD001 treatment results 
in tumor regression and a strong cytotoxic response in vivo. 
 
2.3.5 Co-inhibition durably suppresses mTORC1 signaling via AKT 
We next turned to identification of the mechanisms driving the increased efficacy of the drug 
combination. Because most PI3K-pathway inhibitors (including rapamycin and RAD001) elicit 
feedback signals resulting in incomplete suppression of mTOR and drug resistance11,24, we first 
asked whether the combination of MLN8237 enhanced the activity of RAD001 on mTOR 
signaling to effectors RPS6 (S6) and 4E-BP1 in vivo. Though we observed an incomplete and 
partial suppression of S6 in RAD001-treated MCF7 xenografts, the addition of MLN8237 
resulted in a durable and complete loss of S6 in all nine tumors (Fig. 2.5a). Though RAD001 is a 
relatively potent inhibitor of S6, it is a weak inhibitor of 4E-BP1, and therefore only partially 
impairs cap-dependent protein synthesis24. We thus investigated the activity of phospho-4E-
BP1, which can be stimulated by rapamycin treatment24. Although phospho-4E-BP1 levels were 
enhanced with RAD001 single-agent treatment, co-treatment with MLN8237 suppressed these 
levels back to nearly baseline (Fig. 2.5a). This surprising finding led us to ask how Aurora kinase 
inhibition might alter this key signaling output of mTOR. We investigated AKT activity via 
phosphorylation of serine 473, which activates mTOR and is catalyzed by a variety of kinases25. 
Single-agent MLN8237 reduced phospho-AKT levels in both monotherapy and combination 
treatments, indicating that Aurora kinases sustain mTOR levels by promoting AKT activity 
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(Fig. 2.5a). We next examined whether Aurora-kinase-driven maintenance of mTOR was a 
general feature of PI3K-pathway inhibitors. Using MCF7 cells in vitro, we observed that 
MLN8237 treatment impaired phospho-AKT and that the combination of MLN8237 with 
either GDC-0941 (targeting PI3K) or MK2206 (targeting AKT) led to robust ablation of 
phospho-S6 and phospho-4E-BP1 levels (Fig. 2.5b). Therefore, Aurora kinases contribute to 
resistance to PI3K-pathway inhibitors through the maintenance of AKT and residual mTORC1 
activity. Hence, targeting this survival mechanism results in a more durable and complete 
repression of the PI3K pathway. 
 
2.3.6 Co-inhibition unbalances pro- and antiapoptotic factors 
As we observed cell death in response to these drug combinations (Figs. 2.4d and 2.5b), we next 
sought to elucidate how Aurora kinase mediates cell survival in response to PI3K-pathway 
suppression. Aurora kinases and mTOR both regulate a number of components of the intrinsic 
apoptosis pathway22,26, and we hypothesized that deregulation of the balance of pro- and 
antiapoptotic factors may cause cell death in response to drug combinations containing 
MLN8237. BAX promotes apoptosis, whereas BCL2 prevents apoptosis by inhibiting the 
activity of BAX, and together the balance of these two proteins forms a molecular rheostat for 
apoptosis27. In MCF7 xenografts, combination treatment resulted in an increase in BAX levels 
and a reduction in BCL2 levels, leading to an increase in the ratio of BAX/BCL2 compared to 
either MLN8237 or RAD001 treatment alone (Fig. 2.5c). Furthermore, the BAX/BCL2 ratio 
was also increased by the addition of MLN8237 to GDC-0941, MK2206 or RAD001 in MCF7 
cells in vitro, in which it was associated with the presence of cleaved PARP (Fig. 2.5b,d). Taken 
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together, we propose a model whereby Aurora kinase inhibitors potentiate the activity of PI3K-
pathway inhibitors by enabling a durable and complete suppression of AKT/mTOR signaling 
and drive cell death by altering the balance of pro- and antiapoptotic factors (Fig. 2.5e). 
 
2.3.7 MYC regulates AURKA downstream of the PI3K pathway 
We next sought to identify factors that regulate AURKA in response to PI3K-pathway 
inhibition. We noted that a MYC target gene signature was among the most suppressed gene 
sets after treatment with BYL719, suggesting that MYC may play a significant role in regulating 
the transcriptional response to PI3K inhibition and therefore potentially AURKA (Fig. 2.2e). To 
directly define whether MYC activity is suppressed by PI3K-pathway inhibition, we 
transcriptionally profiled an isogenic pair of MCF10A breast epithelial cells overexpressing 
MYC to derive a gene signature of the top 150 most upregulated genes by MYC (Supplementary 
Dataset 2.4). Comparison of this signature to transcriptional changes induced by BYL719 
treatment in MCF7 and T47D cells revealed that most MYC signature genes were strongly 
repressed during PI3K inhibition (Fig. 2.6a,b). Therefore, MYC is regulated by the PI3K 
pathway in these cells, likely via mTORC1-mediated translation and AKT-mediated 
stabilization of MYC28–30. AURKA was among the signature genes, and we found that MYC-
overexpressing cells had an eight-fold increase in AURKA transcript levels as well as higher 
levels of total and phosphorylated AURKA protein (Fig. 2.6c,d). These data provide direct 
evidence that MYC regulates AURKA abundance and activity and suggest that both are 
controlled by the PI3K pathway in breast cancer. 
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Considering that AURKA activates AKT (Fig. 2.5b)31,32, our results suggest a model whereby 
the PI3K pathway regulates the abundance of its upstream activator AURKA through the 
control of MYC. Hence, MYC-driven AURKA signaling may constitute a positive feedback 
loop that helps to continuously activate the PI3K pathway, even in the context of single-agent 
drug treatment. In support of this theory, we observed that MCF10A-MYC cells were more 
resistant to GDC-0941 and MK2206 compared to parental cells, consistent with previous 
reports of MYC driving resistance to inhibitors of this pathway (Fig. 2.6e,f; Supplementary 
Fig. 2.19a,b)33–36. Although MYC-expressing cells were drug resistant, they could be resensitized 
to GDC-0941 or MK2206 by the addition of MLN8237 until they were back to approximately 
the same relative IC50 as parental cells with this combination (Fig. 2.6e,f; Supplementary 
Fig. 2.19a,b), indicating that AURKA is principally responsible for causing the resistance to 
PI3K inhibition seen as a result of MYC activation in this model. 
 
To test this model, we asked whether MYC-driven resistance to PI3K inhibitors occurs through 
the maintenance of PI3K-pathway activity and if this is dependent on AURKA. GDC-0941 
treatment in MCF10A cells led to a reduction in MYC and AURKA signaling, as well as 
phospho-S6 and phospho-4E-BP1, indicating that MYC and AURKA are regulated by the 
PI3K pathway (Fig. 2.6g). However, constitutive expression of MYC resulted in the 
maintenance of all of these factors after PI3K inhibition, suggesting that MYC also acts 
upstream of the PI3K pathway and can maintain its activity. Furthermore, maintenance of 
mTORC1 signaling by MYC overexpression was reversed by co-inhibition of AURKA, thus 
designating AURKA as the critical link between MYC and activation of the PI3K pathway in 
these cells (Fig. 2.6g). Similar results were observed using the AKT inhibitor MK2206 
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(Supplementary Fig. 2.19c). Taken together, our data define a novel circuit whereby the PI3K 
pathway regulates the abundance of its own activator through MYC-mediated transcription of 
AURKA (Fig. 2.6h). 
 
 
2.4 Discussion  
 
Through an unbiased proteomics approach to assay kinase activity, we measured dynamic 
changes elicited by therapy as a means to develop novel drug combinations. The systematic 
measurement of kinome dynamics across a diverse set of cell lines allowed us to map molecular 
changes associated with resistance to a variety of inhibitors, which is unique from previous 
approaches limited to a single drug or cell line7,15,37. We found a number of cases in which failure 
to inhibit a particular kinase was associated with drug resistance. As our proteomic screen 
included multiple drugs that impinge on distinct oncogenic pathways, we found it surprising that 
a set of common survival factors were identified. This may be due to the convergence of both the 
PI3K and MAPK pathways on protein synthesis38,39. Beyond AURKA, we identified that CDK4 
suppression was associated with drug sensitivity and that the combination of CDK4 and PI3K-
pathway inhibitors was synergistic, consistent with previous work12. Future work may determine 
if other candidates we identified also act as survival factors and how they might do so. 
 
We show that the expression of AURKA limits the efficacy of PI3K-pathway-targeted therapy 
and thus represents a new vulnerability that can be used to enhance therapeutic responses to this 
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class of drugs. By investigating AURKA regulation, we found that the reduction in AURKA 
abundance in drug-sensitive cells appears to be the result of transcriptional control by MYC, 
which is in turn regulated by the PI3K pathway. MYC has been shown to regulate AURKA 
transcription in multiple tumor types40–42 and has independently been associated with resistance 
to PI3K inhibitors, which may be clinically relevant but remains mechanistically ambiguous33–36. 
Here we show that MYC-driven AURKA activation results in maintenance of the PI3K 
pathway despite PI3K inhibitor treatment, resulting in drug resistance. Future work may gauge 
the relative importance of AURKA relative to other outputs of MYC in driving resistance to 
PI3K inhibitors. 
 
Maintenance of AURKA was sufficient to confer drug resistance in a variety of cell lines, as 
evident by the widespread drug synergy observed. We show that in response to treatment with 
PI3K-pathway inhibitors, Aurora kinase maintains the activation of AKT and drives residual 
mTOR activity. Co-inhibition of the PI3K pathway and AURKA with MLN8237 fully blocks 
this residual mTOR activity, resulting in cell death. These findings also highlight the importance 
of AKT activation through serine 473 as a route of drug resistance. Because a number of kinases 
have been shown to operate at this site, including mTORC225, it remains unclear whether 
Aurora kinases act on this site directly or indirectly. These studies elaborate a positive feedback 
loop whereby the PI3K pathway promotes the expression of AURKA, which in turn activates 
the pathway via AKT. One feature of such a positive-feedback loop is the creation of switch-like 
outputs resulting in heightened stability and resistance to perturbation43. We postulate that such 
loops are common and may lead to the resiliency and adaptation that is a hallmark of the PI3K 
pathway and a major cause of the challenges in targeting it therapeutically. Delineating such 
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loops may be an important strategy in identifying effective drug combinations. As a case in point, 
we show that eliminating this positive-feedback loop by blocking AURKA renders cells more 
sensitive to PI3K inhibitors. 
 
Our findings reveal that the combination of Aurora kinase inhibitors and PI3K-pathway 
inhibitors is synergistic and could be a promising clinical strategy to enhance the treatment 
response in breast cancer. These data are consistent with observations made in other settings44–46. 
Clinical data of PI3K and mTOR inhibitors have shown only modest benefit in breast cancers, 
at best resulting in short-term disease stabilization in patients23,47. Consistent with these clinical 
observations, most inhibitors in this class cause only a proliferative arrest in vitro5,21 and it has 
been proposed that combinations that induce apoptosis may be used to enhance responses48. In 
contrast to cytostatic combinations with the CDK4/6 inhibitor (i.e., synthetic sickness), we 
found that combinations with Aurora kinase inhibitors were synergistic and potently induced cell 
death. As clinical trials testing CDK4/6 inhibitor combinations are ongoing, it remains to be 
seen what impact this distinction will play on patient responses. These results warrant an 
expanded analysis of combinations with AURKA inhibitors in additional patient-derived models 
of breast cancer and other cancer types. Tested as monotherapy, Aurora kinase inhibitors have 
reached phase 3 clinical trials for lymphoma with manageable toxicities but limited efficacy49. 
Given that the most common adverse events of PI3K-pathway inhibition are hyperglycemia, rash 
and gastrointestinal toxicity, and that those of Aurora kinase inhibition are primarily 
neutropenia, we are encouraged that the nonoverlapping toxicity profile between the two agents 
may be tolerated in patients as they were in our in vivo studies. As single-agent responses to both 
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PI3K-pathway and Aurora kinase inhibitors have been modest, these findings may unlock the 
full potential of these agents in realizing a clinical benefit. 
 
 
2.5 Methods  
 
2.5.1 Breast cancer cell lines and reagents 
BT549 and SKBR3 cells were obtained from the UCSF Cell Culture Facility. BT20, BT474, 
HCC1428, HCC38, LY2, MCF7, MDAMB231, MDAMB453, T47D, SUM52PE, and 
ZR75B cell lines were obtained from the American Type Culture Collection (ATCC). Cell lines 
used for proteomic profiling and molecular analyses were authenticated by STR analysis. Lines 
were grown according to published protocols50 except for SKBR3, which was cultured using 
RPMI media supplemented with 10% FBS and 1% pen/strep. All cell lines tested negative for 
mycoplasma contamination. Drugs used for cell culture experiments in this study were purchased 
from Selleck Chemicals (GDC-0941, MK2206, PD0325901, lapatinib, MLN8237, and 
LEE011) and LC Laboratories (RAD001). 
 
2.5.2 Multiplex inhibitor bead (MIB) analysis 
Multiplexed inhibitor bead enrichment and MS analysis (MIBs/MS) were performed as 
described previously14. In summary, a selection of bait compounds were purchased or synthesized 
and immobilized on sepharose using standard peptide coupling chemistry. The following 
compounds were purchased commercially: bisindolylmaleimide X (Enzo Life Sciences); 
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SB202190, staurosporine (LC Labs); purvalanol B (Tocris); lapatinib, crizotinib, dasatinib 
(Selleckchem). When not commercially available without modification, linkable versions of 
previously described compounds were synthesized based on prior methods: VI-1683251,52, Akti-
4653, PP-hydroxyl54, sorafenib55, and JG-456 with minor adjustments made for synthetic 
tractability. After initial pilot syntheses and validation, compounds were synthesized by 
Pharmaron, Inc. Louisville KY. Couplings were performed overnight at room temperature (20–
25 °C) on a rotator. Beads and compounds were mixed in 1:1 of dimethyl formamide:ethanol 
with 0.1 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. 
 
After 24-h treatment with drug or DMSO, cell lysates were diluted in binding buffer with 
1 mol/L NaCl, and kinase enrichment was performed using gravity chromatography following 
preclearing. After washing, the bound kinases were eluted with SDS followed by 
extraction/precipitation, tryptic digest and desalting. Liquid chromatography–tandem mass 
spectrometry (LC–MS/MS) was performed on a Velos Orbitrap (Thermo Scientific) with in-
line high-performance liquid chromatography (HPLC) using an EASY-spray column (Thermo 
Scientific). Peptide identifications were made using ProteinProspector (v5.10.10) and input into 
Skyline for label-free quantification57. 
 
Peptide quantification data were pre-processed before analysis with MSstats v2.3.358. First, 
library peptides and peptides that map to nonkinase proteins were removed. Kinase peptide peak 
area values were log2-transformed and quantile-normalized to correct for variation between 
replicates. Finally, peptides that mapped to multiple kinases were removed, as well as peptides 
that were entirely missing in one or more conditions. For each kinase, the log2 ratio of each 
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drug-treated condition to the DMSO control was estimated using the mixed-effects regression 
model in MSstats. 
 
2.5.3 Drug combination studies 
Cell lines were seeded in 384-well assay plates at a density of 1,000 cells/well in a total volume of 
40 µL/well and incubated at 37 °C, 5% CO2 overnight. Dose matrices were assembled containing 
six-point, four-fold serial dilutions from the top concentration for each agent on the x- and y-
axes. Following 72 h of drug exposure, proliferation and cell death was measured by staining with 
Hoescht (Life Technologies) nuclear dye and YO-PRO-1 (Life Technologies), respectively, and 
analyzed using a Thermo CellInsight High Content microscope. Raw phenotype measurements 
from each treated well were normalized to the median of vehicle-treated control wells and 
examined for synergistic effects between both compounds. 
 
To evaluate drug combinations, we used a Loewe model of drug additivity and calculated a 
synergy score. First, we fit a sigmoidal function to each of the single-agent responses. Next, we 
calculated the expected inhibition for each combination using the Loewe additivity model20. The 
synergy score S was calculated as previously defined59 as a positive-gated inhibition-weighted 
volume over of Loewe additivity: 
𝑆 = 𝑙𝑛𝑓!𝑙𝑛𝑓! max (0, 𝐼!"#")max (0, 𝐼!"#" − 𝐼!"#$#) 
Where 𝑓! and 𝑓! are the dilution factors used for compounds X and Y, respectively, 𝐼!"#" is the 
matrix of inhibition data at this dilution factor, and 𝐼!"#$# is the expected inhibition according to 
Loewe additivity. Synergy score calculations were also derived using Bliss independence20, based 
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on a model in which drugs act independently of each other. CI50 values for equal-dose 
combinations were calculated as previously defined20: 
𝐶𝐼!" =  (𝐷)!(𝐷!")! +  (𝐷)!(𝐷!")! 
Where (𝐷)!  and (𝐷)!  are the given doses of the two drugs, and (𝐷!")!  and (𝐷!")!  are the 
IC50 values for each drug as a single agent. 
 
To determine a cutoff for the synergy score, we simulated the distribution of scores generated by 
an additive drug combination. We generated two hypothetical compounds by sampling random 
shape parameters for their dose–response functions and calculated the expected Loewe model of 
the combination. We then added normally distributed noise to the model with variance 
estimated from our experimental data and calculated the resulting synergy score. This process 
was repeated 100,000 times to simulate the distribution of synergy scores for different additive 
combinations. The 95th percentile of this distribution was 0.91 and so we conservatively 
identified combinations with S ≥ 1 as synergistic. 
 
2.5.4 Western blotting and antibodies 
Proteins were extracted using RIPA buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.1% 
sodium deoxycholate, 0.1% SDS, 1 mM EDTA pH 8.0, 1% NP-40) containing proteinase 
(Roche) and phosphatase (Roche) inhibitor cocktails. Samples were resolved using 4–12% SDS–
PAGE gels (Life Technologies) and transferred to PVDF membranes (Millipore). Membranes 
were probed overnight on a 4 °C shaker with primary antibodies (1:1,000 dilution unless 
indicated) recognizing the following proteins: p-AKT (Ser473) (9271, Cell Signaling), AKT 
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(4691, Cell Signaling), p-S6 (Ser240/244) (5364, Cell Signaling, 1:20,000), p-4E-BP1 
(Thr37/46) (2855, Cell Signaling), p-AURKA (Thr288) (3079, Cell Signaling), AURKA (4718, 
Cell Signaling), Cleaved PARP (Asp214) (9541, Cell Signaling), BCL2 (2870, Cell Signaling), 
BAX (2772, Cell Signaling), MYC (ab32072, Abcam), and β-actin (3700, Cell Signaling). 
 
2.5.5 Mouse xenograft studies 
All animal studies were conducted in compliance with all relevant ethical regulations set forth by 
the UCSF Institutional Animal Care and Use Committee (IACUC). 4-week old 
immunocompromised NOD/SCID female mice were purchased from Taconic Biosciences, and 
MCF7 cells used for in vivo transplant were obtained from the UCSF Preclinical Therapeutics 
Core. Xenograft tumors were initiated in the cleared mammary fat pads of mice bearing slow 
release estrogen pellets (Innovative Research of America) by orthotopic injection of 1 × 
106 MCF7 cells in a 1:1 mixture of serum-free medium and Matrigel (BD Biosciences). When 
tumors reached ≥ 1 cm in any direction via electronic caliper measurements, mice were 
randomized into cohort groups and treatment was initiated. 
 
Treatment arms received either vehicle (1:1 mixture of single-agent diluents), RAD001 
formulated as a microemulsion (2 mg/kg/q; 30% propylene glycol, 5% Tween 80), MLN8237 
(10 mg/kg/q; 10% 2-hydroxypropyl-β-cyclodextrin, 1% sodium bicarbonate), or the combination 
daily via oral gavage. Animals were monitored daily for evidence of toxicity, including weight 
and skin effects, and changes in tumor size (mm3) through bidirectional measurements of 
perpendicular diameters using electronic calipers, and calculated as 𝑉 =  1 2 (𝑙𝑒𝑛𝑔𝑡ℎ×𝑤𝑖𝑑𝑡ℎ!). 
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Mice were sacrificed after 15 d of treatment, following which tumors were excised and a portion 
of the tissue fixed in 4% paraformaldehyde. The remaining tumor tissue was flash-frozen in 
liquid nitrogen. 
 
2.5.6 Immunohistochemical analysis 
PFA-fixed tumor samples were paraffin-embedded, and immunohistochemical staining of tissue 
sections was performed. TUNEL staining was carried out using the ApopTag Peroxidase In situ 
Apoptosis Detection Kit (Millipore) according to the manufacturer’s instructions (n = 15 data 
points per group; five high-powered (20×) fields analyzed from separate areas of each tumor from 
3 mice per experimental group). Stained slides were digitized using the Leica DMi1 Microscope 
(Leica Microsystems) with a 20× objective. Images were scored as the number of TUNEL-
positive cells per captured field, and quantification was performed in a manner that was blinded 
to treatment group. 
 
2.5.7 Real-time PCR 
RNA was isolated according to the manufacturer’s instructions (TRIzol, Life Technologies). 
One microgram of total RNA from each sample was subjected to first-strand cDNA synthesis 
according to the manufacturer’s recommendations (Promega). Quantitative PCR was performed 
on a CFX96 Real-Time PCR detection system with a PrimeTime Gene Expression Master Mix 
(IDT technology) according to the manufacturer’s protocol. AURKA was amplified with the 
following primers: 5′-AGTTGGCAAACGCTCTGTCT-3′ (forward primer) and 5′-
GTGCCACACATTGTGGTTCT-3′ (reverse primer). RPL13A was used as an endogenous 
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control with the following primers: 5′-CGGATTTGGTCGTATTGG-3′ (forward primer) and 
5′-TCCTGGAAGATGGTGATG-3′ (reverse primer). The cycling conditions for AURKA 
and RPL13A were as follows: one cycle at 95 °C for 3 min; 40 cycles of 95 °C for 15 s, and 60 °C 
for 60 s. The specificity of the PCR amplification was validated by the presence of a single peak 
in the melting curve analyses. 
 
2.5.8 Gene Set Enrichment Analyses (GSEA) 
Gene set enrichment analysis (GSEA) of hallmark cancer gene signatures in the Molecular 
Signatures Database (MSigDB v6.0) was performed using GSEA v3.0 software 
(http://www.broadinstitute.org/gsea/)19 under the following parameters: permutation, phenotype; 
metric, Signal2Noise; scoring scheme, weighted; and number of permutations, 1,000. Gene sets 
were considered significantly enriched following a nominal P < 0.05 and FDR < 0.25 cutoff. 
 
2.5.9 Statistical analysis 
Data are expressed as means ± s.d., unless otherwise indicated. Statistical analyses were 
performed using GraphPad Prism 6 (v6.0 g) and R (v3.32). Two-tailed Student t- tests (with 
unequal variance) were used in all comparisons unless otherwise noted. P < 0.05 was considered 
statistically significant throughout the study. 
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2.5.10 Reporting Summary 
Further information on experimental design is available in the Nature Research Reporting 
Summary (https://www.nature.com/articles/s41589-018-0081-9#MOESM2) linked to this 
article. 
 
2.5.11 Data availability 
All data generated or analyzed during this study are included in this published article and its 
supplementary information files. The raw mass spectrometry data is accessible 
via http://prospector2.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msviewer under the search 
key: lixlgarvea. 
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2.8 Figures  
 
Figure 2.1 Measurement of kinome dynamics to identify correlates of drug sensitivity. (a) 
Schematic of the approach using multiplexed inhibitor beads followed by MS (MIBs/MS). 
Sample lysates are passed through a column containing the indicated kinase inhibitors covalently 
linked to beads. After washing, bound proteins are eluted, trypsin digested and quantified 
through label-free MS. (b), Human kinome tree annotated with kinases identified in this study, 
colored based on the percentage of total samples, whereby each particular kinase could be 
quantified. (c) Comparison of activity ratios between biological replicates for 122 kinases, 
expressed as a log ratio of measurements from SKBR3 cells treated with 200 nM lapatinib for 
24 h versus DMSO. Pearson correlation and P value are shown. (d) Comparison of kinase 
activity ratios in BT549 and MCF7 cells treated with 100 nM PD0325901 versus DMSO. Data 
represent 75 kinases with one outlier kinase (GAK, BT549 log2 fold change 8.3) removed. (e) 
Comparison of activity ratios for 70 kinases measured from MCF7 cells treated with either 
250 nM MK2206 or GDC-0941 compared to DMSO. (f) Categorical analysis of kinome 
dynamics occurring in drug-sensitive treatment responses (n = 6) versus resistant treatment 
responses (n = 14) for all drugs pooled together. For visualization purposes, each kinase was 
centered on the mean of resistant samples. Data are shown for 75 kinases, which could be 
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measured in > 75% of samples. All drug treatments are 24 h. Error bars are mean ± s.e.m., 
and P values were calculated using a two-sided t-test. 
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Figure 2.2 Maintenance of AURKA is associated with resistance to PI3K inhibition. (a) 
Changes in activity of AURKA as measured by MIBs in drug-sensitive versus drug-resistant 
treatment responses after 24 h of exposure to the indicated compounds. Each point reflects a 
single cell line and drug treatment (n = 20 biologically independent samples). Box-and-whisker 
plots show median (centerline), upper/lower quartiles (box limits), and whiskers spanning the 
interquartile range from 25–75 percentiles. P value was calculated using a two-sided t-test. (b) 
Western blot showing PI3K and AURKA signaling in GDC-0941-resistant and GDC-0941-
sensitive cell lines. Protein lysates from cells treated with 1 µM GDC-0941 were extracted at 
different time points, separated by SDS–PAGE, and analyzed by immunoblot with the indicated 
antibodies. Image represents n = 3 independent experiments (full blots shown in Supplementary 
Fig. 2.8). (c,d) Log ratio expression values of AURKA mRNA measured by RT-PCR from the 
indicated cell lines treated with 1 µM of GDC-0941 (c) or 1 µM MK2206 (d) for 24 h compared 
to DMSO treatment. Data represents n = 3 biological replicates. Error bars are mean ± s.e.m., 
and P values were calculated using one-way ANOVA. (e) Gene Set Enrichment Analysis 
(GSEA) of top gene sets significantly upregulated or downregulated after 24 h in response to 
1 µM BYL719 treatment in MCF7 and T47D cells compared to DMSO. Data in e were based 
on transcriptomic data from Bosch et al.17. PI3Ki, PI3K inhibitor; AKTi, AKT inhibitor.  
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Figure 2.3 AURKA suppression enhances sensitivity and drives cell death in response to PI3K-
pathway inhibitors in breast cancer cell lines. (a) A dose matrix of GDC-0941 (PI3Ki), 
MK2206 (AKTi), or RAD001 (mTORi) in combination with the AURKA inhibitor MLN8237 
in MCF7 cells. Cell proliferation was assessed after 72 h. Percent growth inhibition at each dose 
is shown. (b) Synergy scores based on a Loewe excess inhibition model across 13 breast cancer 
cell lines that were treated with the indicated combinations using an escalating dose matrix for 
72 h. Dashed line indicates a 5% FDR cutoff to define synergistic combinations 
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(see Methods). (c) Cell lines were treated with 625 nM of the indicated single agents or those 
combined together for 72 h, and apoptosis was measured by YO-PRO1 positivity. Data 
represents n = 4 biologically independent samples. Error bars are mean ± s.d., and P values were 
calculated using a two-sided t-test. PI3Ki, PI3K inhibitor; AKTi, AKT inhibitor; mTORi, 
mTOR inhibitor. 
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Figure 2.4 The Aurora kinase inhibitor MLN8237 enhances sensitivity to everolimus 
(RAD001) and induces cell death in vivo. (a) MCF7 orthotopic xenograft tumors were treated 
with vehicle (n = 6 biologically independent mice), RAD001 (2 mg/kg/day; n = 7 biologically 
independent mice), MLN8237 (10 mg/kg/day, n = 6 biologically independent mice) or with the 
combination of the two single agents (n = 9 biologically independent mice) via oral gavage, daily, 
over 15 d. The percentage change in tumor volume was calculated for each animal from 
baseline. (b) Individual tumor profiles compared to baseline for each tumor treated with vehicle 
(n = 6 biologically independent mice), RAD001 (n = 7 biologically independent mice), 
MLN8237 (n = 6 biologically independent mice) or the combination (n = 9 biologically 
independent mice) over a 15-d period. (c) Representative images of tumor tissue extracted from 
mice after 15 d of treatment with the indicated agents and stained for H&E and TUNEL. 
Images are shown using a 10× objective. Scale bars, 200 µm. (d) Quantification of the number of 
TUNEL+ cells/field from TUNEL staining of MCF7 tumors following 15 d of treatment. Data 
is an average of five high-powered (20×) fields analyzed per tumor and are representative of n = 3 
biologically independent animals. In all graphs, error bars are mean ± s.d., and P values were 
calculated using a two-sided t-test. 
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Figure 2.5 Aurora kinase co-inhibition durably suppresses mTORC1 signaling and alters the 
BAX/BCL2 ratio. (a) MCF7 orthotopic xenografts were treated with vehicle (n = 6 biologically 
independent mice), RAD001 (2 mg/kg/day; n = 7 biologically independent mice), MLN8237 
(10 mg/kg/day; n = 6 biologically independent mice) or the combination of the two single agents 
(n = 9 biologically independent mice) for 15 d, at which point tumors were harvested and snap 
frozen. Western blot of protein lysates from individual tumors were probed with the indicated 
antibodies (full blots shown in Supplementary Fig. 2.17a). (b) MCF7 cells were treated with 
either 250 nM GDC-0941, 250 nM MK2206, 5 nM RAD001, 100 nM MLN8237 or the 
indicated combinations for 24 h, and protein lysates were subjected to immunoblot using the 
indicated antibodies. Representative image from n = 3 independent experiments (full blots shown 
in Supplementary Fig. 2.17b). (c) BAX, BCL2 and BAX/BCL2 ratio in MCF7 orthotopic 
xenografts treated for 15 d with the indicated drugs based on quantification of western blot 
images (RAD001, n = 7; MLN8237, n = 6; combination, n = 9 biologically independent mice 
analyzed). (d) BAX/BCL2 ratio in MCF7 cells treated for 24 h with the indicated drugs based 
on quantification of western blot images from n = 3 independent experiments. (e) Proposed 
model of the mechanism of Aurora kinase inhibitor synergy. De novo resistance to single-agent 
inhibition of PI3K, AKT or mTOR is due to incomplete suppression of the pathway because of 
Aurora kinase signaling, which activates AKT. Drug combinations that simultaneously inhibit 
the PI3K pathway and block Aurora kinase signaling completely suppress mTOR signaling to 
4E-BP1 and S6, resulting in tumor cell death. In all graphs, error bars are mean ± s.e.m., 
and P values were calculated using a two-sided t-test.  
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Figure 2.6 AURKA transcription is regulated by MYC downstream of the PI3K pathway. (a,b) 
Histogram of normalized gene expression of all 150 genes in the MYC gene signature compared 
to genes not in this signature for MCF7 (a) or T47D (b) cells treated with 1 µM BYL719 or 
DMSO for 24 h. BYL719 treatment data were obtained from Bosch, et al.17 and P values 
determined by Kolmogorov–Smirnov test. Black arrows highlight differences in distribution of 
MYC signature genes. (c) Relative levels of AURKA mRNA in an isogenic pair of control 
(PURO, n = 3 independent samples) or MYC-expressing MCF10A cells (n = 2 independent 
samples) measured by RT-PCR. (d) Immunoblot of protein lysates from PURO or MYC cells 
representative of n = 3 independent experiments with similar results (full blots shown in 
Supplementary Fig. 2.18a). (e) Proliferation of control or MYC cells in response to GDC-0941 
alone or in combination with 2.5 nM MLN8237. Combinations were normalized to MLN8237 
alone. Data represent n = 4 biologically independent samples. (f) IC50 analysis of dose–response 
curves shown in e from n = 4 independent samples. (g) Immunoblot of lysates from control and 
MYC MCF10A cells treated with 1 µM GDC-0941 or 100 nM MLN8237 for 24 h. 
Representative image of n = 3 independent experiments with similar results (full blots shown in 
Supplementary Fig. 2.18b). (h) Proposed model of positive feedback loop between the PI3K 
pathway, MYC and AURKA. In all graphs, error bars are mean ± s.d., and P values were 
calculated using a two-sided t-test, unless otherwise indicated. 
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2.9 Supplementary Figures  
 
Supplementary Figure 2.1 Structure of drugs bound to multiplex inhibitor bead column. 
Displayed are the inhibitors that were used for the generation of inhibitor-based beads that were 
assembled for the MIB kinome enrichment. 
  
	 55 
 
Supplementary Figure 2.2 Dependence of MIBs data on gene expression. Baseline RNAseq 
data from each listed cell line was obtained and kinases classified into three categories into high, 
moderate and low expression. For each cell line, the fraction of kinases expressed at each level 
that were captured and quantified in the MIBs dataset are shown. RNAseq data downloaded 
from www.synapse.org/#!Synapse:syn2346643/wiki/62255. 
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Supplementary Figure 2.3 Diversity analysis of breast cancer cell lines. Hierarchical clustering of 
transcriptional profiles across a panel of breast cancer cell lines. The top 1,000 most differentially 
expressed genes were used for clustering. Cell lines annotated based on receptor, mutation and 
subtype status. Cell lines used for MIBs profiling highlighted in blue. RNAseq data downloaded 
from www.synapse.org/#!Synapse:syn2346643/wiki/62255. 
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Supplementary Figure 2.4 Characteristics of breast cancer cell lines used for kinome profiling. 
(a) Table of breast cancer cell lines used in this study with the indicated molecular subtypes and 
mutational status. (b) Drug sensitivity of cell lines indicated by IC50 and categorized into relative 
drug sensitivity or resistance. Because IC50 was not reached for PD0325901, IC25 is shown. 
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Supplementary Figure 2.5 Drug-specific analysis of kinome changes highlight commonalities 
with previous reports. Observed kinome changes (shown as kinase log ratios) for Lapatinib 
treated SKBR3 cells from in-house MIBs/MS screening data in comparison to kinases measured 
from published dataset (Stuhlmiller, et al.)15. Kinases reported as having significant changes in 
activity after treatment from the Stuhlmiller, et al. study are depicted in red. Correlation 
computed over n = 31 kinases for red and n = 104 kinases for gray. 
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Supplementary Figure 2.6 Cell line dose response analysis and correlation with sensitivity. (a-d) 
Cell lines used for the MIBs screening panel were grown in the presence of the indicated 
compounds and allowed to proliferate for 72 h. Relative proliferation compared to DMSO was 
scored using cell count and based on n = 4 biologically independent samples. (e) Annotation of 
drug sensitivity using three drug response categories (resistant, moderately sensitive and highly 
sensitive) based on the indicated IC50 values. Because IC50 was not reached for PD0325901, IC25 
is indicated. (f) Correlation of kinase activity scores with treatment response. Kinase activity 
scores were correlated with the following treatment response values: resistant, 3; moderate, 2; 
sensitive, 1. Positive correlations indicate kinases whose activity was higher in resistant treatment 
response conditions. Dotted line indicates P = 0.05 based on the P value of correlation. Each 
point correlation computed over n = 20 biologically independent samples. (g) Activities of 
AURKA across the three treatment response categories. Each point reflects a single cell line and 
drug treatment, for a total of n = 20 biologically independent samples. Box-and-whisker plots 
show median (centerline), upper/lower quartiles (box limits), and whiskers spanning the 
interquartile range from 25-75 percentiles. P values calculated using a two-sided t-test. 
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Supplementary Figure 2.7 Drug-specific analysis of MIBs/MS data. (a) Ranked lists of kinome 
dynamics comparing drug sensitive cells versus resistant cells for each drug independently. For 
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each kinase the level of change was expressed as log ratio of treated/DMSO and this ratio 
compared between sensitive and resistant cell lines. Kinases were scored independently for each 
drug (drug-specific analysis; n = 98 GDC-0941, n = 98 MK2206, n = 106 Lapatinib, n = 101 
PD0325901) or using a pooled approach (drug-agnostic analysis; n = 75 pooled). Significant 
differences between sensitive and resistant cells are starred (P < 0.05). (b) Levels of AURKA 
defined as log2 fold change (treatment/DMSO) in sensitive (S) or resistant (R) cells to the 
indicated inhibitors, displayed by individual drugs or pooled together among all drugs surveyed. 
Each point reflects a single cell line and drug treatment, for a total of n = 20 biologically 
independent samples pooled together. Bars represent data mean and P values calculated using a 
two-sided t-test. 
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Supplementary Figure 2.8 Full blot images of Figure 2.2b. Regions surrounded by red boxes are 
presented in Fig. 2.2b of the main text.  
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Supplementary Figure 2.9 GDC-0941 and MK2206 validation in sensitive and resistant cell 
lines. (a,b) Quantification from Fig. 2.2b of total AURKA (a) and p-AURKA (b) levels from 
cells treated with 1 µM GDC-0941 over 24 h. (c) Immunoblot analysis of PI3K-pathway and 
AURKA signaling from protein lysates of cell lines treated with 1 µM MK2206 for the indicated 
periods of time. (d,e) Quantification of total AURKA (d) and p-AURKA (e) levels of cell lines 
treated with 1 µM MK2206 over 24 h from panel (c). For all quantifications, densitometry was 
performed using ImageJ software, and signal intensities were normalized to β-actin loading 
controls. (a-e) are representative of n = 3 independent experiments with similar results.  
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Supplementary Figure 2.10 PI3K inhibition suppresses transcription of factors involved in 
G2/M checkpoint. (a) Relative expression of AURKA mRNA from MCF7 or T47D cells 
treated with 1 µM BYL719 for 24 h (n = 3 biologically independent samples). IC50 from Leroy, 
et al.18 Error bars are mean ± s.d. and P values calculated using a two-sided t-test. (b) Leading 
edge analysis of expression of genes involved in the G2/M checkpoint gene signature. Negative 
normalized enrichment score (NES) indicates that genes in this set were enriched to be 
downregulated in response to BYL719 treatment. Normalized transcript levels for 190 genes in 
this set measured in triplicate is shown. In all graphs, data based on transcriptomic data from 
Bosch, et al.17 
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Supplementary Figure 2.11 Drug synergy analysis for combinations of GDC-0941 and the 
Aurora kinase inhibitor MLN8237. Analysis of proliferation data from cells treated with the 
indicated drug combinations for 72 h. (a) Dose-escalation matrices showing percent growth 
inhibition of cell lines treated with MLN8237 in combination with GDC-0941. (b) Loewe 
excess values representing growth inhibition over an additive model. (c) Bliss excess values 
representing growth inhibition assuming drug independence. (d) Combination Index (CI) values 
based on 1:1 dose combinations. Teal regions represent synergistic CI values. Dotted lines 
indicate areas of strong synergy (CI < 0.3), moderate synergy (0.3-0.7), slight synergy (0.7-1) and 
antagonism (CI > 1.2). Cell line names are listed along with the derived synergy score in 
parenthesis. For clarity, exceptionally high CI values were cutoff at 2.  
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Supplementary Figure 2.12 Drug synergy analysis for combinations of MK2206 and the Aurora 
kinase inhibitor MLN8237. Analysis of proliferation data from cells treated with the indicated 
drug combinations for 72 h. (a) Dose-escalation matrices showing percent growth inhibition of 
cell lines treated with MLN8237 in combination with MK2206. (b) Loewe excess values 
representing growth inhibition over an additive model. (c) Bliss excess values representing 
growth inhibition assuming drug independence. (d) Combination Index (CI) values based on 1:1 
dose combinations. Teal regions represent synergistic CI values. Dotted lines indicate areas of 
strong synergy (CI < 0.3), moderate synergy (0.3-0.7), slight synergy (0.7-1) and antagonism (CI 
> 1.2). Cell line names are listed along with the derived synergy score in parenthesis. For clarity, 
exceptionally high CI values were cutoff at 2.  
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Supplementary Figure 2.13 Drug synergy analysis for combinations of RAD001 and the Aurora 
kinase inhibitor MLN8237. Analysis of proliferation data from cells treated with the indicated 
drug combinations for 72 h. (a) Dose-escalation matrices showing percent growth inhibition of 
cell lines treated with MLN8237 in combination with RAD001. (b) Loewe excess values 
representing growth inhibition over an additive model. (c) Bliss excess values representing 
growth inhibition assuming drug independence. (d) Combination Index (CI) values based on 1:1 
dose combinations. Teal regions represent synergistic CI values. Dotted lines indicate areas of 
strong synergy (CI < 0.3), moderate synergy (0.3-0.7), slight synergy (0.7-1) and antagonism (CI 
> 1.2). Cell line names are listed along with the derived synergy score in parenthesis. For clarity, 
exceptionally high CI values were cutoff at 2.  
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Supplementary Figure 2.14 Induction of apoptosis in selected single agent and drug 
combinations. (a) Surface plot of YO-PRO1 positivity for dose-escalation matrix of the 
combination of MK2206 and MLN8237 in MCF7 cells treated with the indicated dose for 72 h. 
(b) Fold change in YO-PRO1 positivity compared to DMSO for indicated single agent and 1:1 
combinations. P values shown for cases where the level of apoptosis in the combination was 
significantly higher than either single agent alone. Red labels indicate cell lines which were 
deemed to be synergistic based on a synergy score > 1. (c) Surface plot of YO-PRO1 positivity 
across the dose-escalation matrix and (d) fold change in apoptosis for cells treated with indicated 
single agent and combinations with the CDK4/6 inhibitor LEE011. (e) Apoptosis compared to 
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DMSO treatment in cell lines treated with 625 nM of the indicated single agents or combined 
for 72 h. Apoptosis measured by YO-PRO1 positivity. In all graphs, data are based on n = 4 
biologically independent samples, error bars are mean ± s.d. and P values calculated using a two-
sided t-test. 
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Supplementary Figure 2.15 RAD001 is cytostatic in MCF7 cells. (a) Dose response analysis of 
MCF7 cells exposed to RAD001 for 72 h. Proliferation measured by cell count from n = 4 
biologically independent samples and error bars are mean ± s.d. (b) MCF7 cells were treated 
with the indicated doses of RAD001 for 24 h. Protein lysates were subjected to immunoblot and 
analyzed for PI3K-pathway signaling and cell death using the indicated antibodies. 
Representative image of n = 2 independent experiments with similar results. (c) Dose response 
analysis of proliferation for a panel of 13 breast cancer cell lines following 72 h exposure to 
RAD001 from data based on n = 4 biologically independent samples. 
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Supplementary Figure 2.16 Mouse weight during xenograft studies. Average mouse weight over 
the course of 15 d treatment with vehicle (n = 6 biologically independent mice) or the indicated 
dose of RAD001 (n = 7 biologically independent mice), MLN8237 (n = 6 biologically 
independent mice) or the combination (n = 9 biologically independent mice). Error bars are 
mean ± s.d. and P values calculated using a two-sided t-test. 
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Supplementary Figure 2.17 Full blot images of Figure 2.5. Regions surrounded by red boxes are 
presented in (a) Fig. 2.5a and (b) Fig. 2.5b of the main text.  
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Supplementary Figure 2.18 Full blot images of Figure 2.6. Regions surrounded by red boxes are 
presented in (a) Fig. 2.6d and (b) Fig. 2.6g of the main text. 
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Supplementary Figure 2.19 MYC expression causes resistance to AKT inhibition via AURKA 
mediated activation of the PI3K pathway. (a) Proliferation of control (PURO) or MYC 
MCF10A cells in response to MK2206 or treated with the combination of 2.5 nM MLN8237. 
Combinations were normalized to MLN8237 alone. Data represents n = 4 biologically 
independent samples. (b) IC50 analysis of dose-response curves shown in (a) from n = 4 
independent samples. (c) Immunoblot analysis of lysates from control and MYC MCF10A cells 
treated for 24 h with 1 µM of MK2206 as a single-agent or in combination with 100 nM of 
MLN8237. Representative image of n = 3 independent experiments with similar results. In all 
graphs, error bars are mean ± s.d. and P values were calculated using a two-sided t-test. 
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Chapter 3.  
Single-cell pharmacogenomics targets an inflamed 
chemoresistant tumor subpopulation in triple negative breast 
cancer 
 
3.1 Abstract 
 
Cancers often harbor high levels of intra-tumoral heterogeneity, or differences among individual 
cancer cells, which may directly contribute to drug resistance through the selection of mutant 
subclones. We hypothesized that non-genetic differences in cellular states between individual 
cancer cells may also reflect altered drug sensitivities and as such, can be used to inform upfront 
drug combinations that elicit more complete anti-tumor responses. To capture functional 
heterogeneity we performed single-cell RNA sequencing (scRNAseq) of 5 different in vitro and 
in vivo breast cancer models encompassing 55,000 breast cancer cells. We identified tumor cell 
subpopulations reflective of different subtypes or cellular states associated with resistance to 
standard-of-care therapies in all models analyzed. Notably, we identified a recurrent 
subpopulation present in all triple-negative breast cancer (TNBC) models where a rare fraction 
of cells exist in a reversible interferon-stimulated gene (ISG)-state caused by cGAS/STING 
signaling. Pharmacogenomic modeling based on bulk cancer cell line drug sensitivities predicted 
that ISG cells were chemotherapy resistant and hypersensitive to CDK4/6 and mTOR 
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inhibition, which we experimentally validated. ISG expression is associated with poor prognosis 
and residual disease after chemotherapy in TNBC, implicating this population in disease 
progression and highlighting the need for identifying, modeling and targeting cancer cells in a 
pre-existing drug resistant state.  
 
 
3.2 Introduction  
 
Drug resistance is a major problem in breast cancer where insensitivity to chemotherapy is 
associated with a 40 to 80% risk of recurrence after neo-adjuvant therapy resulting in incurable 
metastatic disease and death for most patients1–3. The need for new therapeutic approaches is 
particularly pressing in the context of triple-negative breast cancers (TNBC), the most aggressive 
subtype of disease accounting for 12 to 18% of all breast cancer cases4, where responses to 
chemotherapy are not durable. In the case of neo-adjuvant chemotherapy, 30 to 50% of patients 
with localized TNBC evolve resistance leading to poor overall survival for this group of 
patients4,5. Similar phenomena has also been observed in respect to targeted therapies, as seen 
with HER2 inhibitor treatment leading to a pathologic complete response (pCR; defined as no 
invasive or in situ residual tumors in the breast) rate of only 25 to 30% in HER2+ breast 
cancers6,7. Although one mode of drug resistance can be attributed to the Darwinian selection of 
pre-existing genetically diverse subclones8–10, clinical evidence from breast cancers undergoing 
neo-adjuvant chemotherapy have indicated treatment often does not result in subclonal selection 
demonstrating that it is not necessarily genetically encoded9,11–13. These properties are also 
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evident in vitro in breast cancer cell lines (BCCLs) and patient-derived xenograft (PDX) models 
that can also evolve drug resistance through genetic and non-genetic mechanisms14–16. To this 
end, cells existing in different cell states can possess differential drug sensitivities further 
complicating the therapeutic management of breast tumors due to the inherent plasticity of 
tumor cell states16–19. Hence new approaches are needed to counteract both genetic and non-
genetic forms of drug resistance in breast cancer. 
 
Molecular variability between individual cancer patients (inter-tumoral heterogeneity) can 
predict who will respond to therapy, such as differences in molecular subtypes, which is crucial in 
determining predicted responsiveness to standard-of-care therapies20–22. As such, classification of 
intrinsic molecular subtype from bulk patient tumor samples has become an important diagnostic 
tool to predict risk of relapse and response to chemotherapy in breast cancers. However, patients 
do not present with homogenous tumors clinically, often times lacking uniform expression of 
therapeutic targets23. This heterogeneity can severely impact the clinical assessment of a tumor 
and subsequent therapeutic regimens, and may facilitate recurrence whereby subpopulations of 
cells are spared during treatment. Similarly, molecular variability among individual cancer cells 
(intra-tumoral heterogeneity) determines which are selected for by therapy. While this variability 
may be genetic in the form of multiple different subclones within a tumor mass being linked with 
resistance9,11–13, this variability may also be non-genetic and even stochastic in nature where 
breast cancer cells in a drug resistant state are present prior to therapy9.  
 
Single-cell DNA- and RNA-sequencing methods have emerged as powerful tools for resolving 
intra-tumoral heterogeneity, reconstructing tumor evolutionary lineages, and characterizing 
	 85 
distinct tumor cell subpopulations in breast cancers9,24,25. However, approaches to use these data 
derived from single-cell studies towards predicting and testing new therapeutic strategies have 
remained a challenge. Studies linking genomics to drug efficacy, or pharmacogenomics, have 
relied on the analysis of large panels of cell lines or PDX systems having been both molecularly 
profiled and functionally challenged through high-throughput drug screens. However, these bulk 
assays have limited application to studying the functional consequences of cell-cell variability in 
that heterogeneous responses of cells from within a bulk population and subtle changes in cell 
state or gene expression are obscured in bulk analysis. Therefore, the functional implications that 
individual cells within a population pose on therapeutic responses remains unknown due to the 
lack in feasibility of directly challenging a single live cell with drug. As such, approaches for 
characterizing genetic and functional variability contributing to drug response at the cellular level 
are needed to inform upfront drug combinations that elicit more complete anti-tumor responses. 
 
Here we hypothesized that the molecular variability between individual breast cancer cells and 
subsequent impact on drug sensitivities could be modeled by the differences observed between 
individual cancer samples and therapeutic outcomes. To test this hypothesis we measured 
transcript levels in single cells from various breast cancer models both in vitro using cell lines and 
in vivo using patient-derived xenograft samples and patient data and identified distinct 
subpopulations in each model tested that predicted resistance to standard-of-care breast cancer 
therapies. One of these populations was identified solely in TNBC samples and was comprised 
of cells in an interferon-stimulated gene (ISG) state whose representative genes were elevated in 
TNBC patient samples and associated with poor outcomes. We developed a computational 
approach to identify signatures of drug resistance and sensitivity based on cell line pharmacologic 
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profiling datasets and patient-derived gene modules, which predicted that ISG cells were 
resistant to chemotherapy, which was experimentally validated in TNBC cells using a single-
live-cell tracking workflow. Pharmacogenomic modeling based on bulk cancer cell line drug 
sensitivities also predicted that ISG cells were hypersensitive to CDK4/6 and mTOR inhibition, 
which we confirmed as an effective strategy for targeting this chemoresistant subpopulation. 
Here we provide an effective new framework to systematically discover drug combinations 
capable of counteracting tumor heterogeneity by predicting drug responses of individual breast 
cancer cells. Our study potentially explains the cellular source of heightened ISG expression 
found in residual TNBC tumors after chemotherapy and systematically links tumor 
transcriptional heterogeneity with drug actionability to optimize therapy combinations. 
 
 
3.3 Results  
 
3.3.1 Single-cell heterogeneity is pervasive across various models of breast cancer  
To first understand the functional consequences of heterogeneity on drug resistance, we analyzed 
the transcript profiles of individual cells from various models of breast cancer including pre-
clinical and patient sample data (Fig. 3.1a). Transcriptional profiling was performed at the 
single-cell level on a panel of cell lines representing various subtypes of breast cancer (MCF7ER+, 
SKBR3HER2, MDA-MB-231TNBC, HCC38TNBC) in addition to freshly dissociated cells from a 
patient-derived xenograft (PDX) model of TNBC (HCI-002PDX-TNBC) using the 10x Genomics 
Chromium™ platform. At an average depth of 23,573 reads per cell, sequencing resulted in an 
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average number of 6,491 unique molecular identifiers (UMIs) and 1,609 genes detected per cell 
following initial quality control filters (Supplementary Dataset 3.1). Overall, we studied the 
expression profiles of 54,599 single cells (3,080 – 19,173 cells per sample) from 5 breast cancer 
models reflecting the different subtypes of disease. Additionally, we obtained single-cell profiles 
of longitudinal tumor samples from a cohort of 8 TNBC patients9 both pre- and-post 
chemotherapy treatment. Together this data constitutes an extensive representation of breast 
cancer heterogeneity and provides a useful resource for studying its functional implications. 
 
To investigate the magnitude of heterogeneity across breast cancer, we performed an 
unsupervised graph-based clustering of all cells pooled from the panel of breast cancer cell lines 
(n = 51,519 cells) using genes from significant principal components, and visualizing the space 
using Uniform Manifold Approximation and Projection (UMAP)26 (Fig. 3.1b). To avoid batch 
effects, all samples were processed together with the exception of HCC38 data. Comparison of 
single cell profiles using a two dimensional UMAP embedding revealed significant heterogeneity 
in cells to the extent that often times cells from one model had high similarity with cells from a 
different model, even through different models were derived from different patients with distinct 
disease subtypes (Fig. 3.1b). To this end, despite cancer cell lines being accepted homogenous 
model systems, we observed a number of cells from every cell line clustering apart from their 
predominant parent cluster. For example, cells from the luminal breast cancer cell line MCF7ER+ 
were found in clusters primarily composed of cells from a basal tumor model. TNBC MDA-
MB-231 cells also appeared highly heterogeneous in that a subpopulation of cells were found 
clustered with both ER+ and HER2-amplified dominated subclusters (Fig. 3.1b). These results 
were largely robust with respect to various methods for measuring cell-cell similarity and 
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clustering (Supplementary Fig. 3.1). Taken together, based on the transcript profiles of 
individual cells this data suggests the existence of subpopulations within homogenous models of 
breast cancer that identify with and may functionally mimic cell types of a different lineage 
separate from the bulk tumor classification. This finding may have significant clinical 
implications given that breast cancer standard-of-care treatment regimens are typically prescribed 
based on subtype classifications. We next investigated if this degree of heterogeneity is reflected 
across patient tumor cells by looking within single-cell profiles from a cohort of TNBC patients9. 
Here we also observed similarities in cell states between 2,640 single cells derived from 8 
treatment-naïve TNBC patients, indicating that the degree of between tumor (inter-tumoral) 
heterogeneity is at least partly matched by the heterogeneity between cancer cells from the same 
tumor (intra-tumoral heterogeneity). Rather than cells from each individual patient clustering 
based on parent sample identity, we observed significant overlap between groups where cells 
from various patients were intermixed in different subclusters (n = 2,640 pre-treatment cells; Fig. 
3.1c). Previous work analyzing the gene expression profiles of 515 breast tumor cells from 11 
patients also found extensive intra-tumoral heterogeneity, corroborating a mixed representation 
of intra- and inter-patient cells24. This suggests that transcriptional diversity occurs in all levels of 
breast cancer models spanning cell lines to patient profiles.  
 
We next asked if this degree of heterogeneity is observed even deeper within individual cell lines 
and samples. To identify distinct subpopulations present within specific samples, we performed 
clustering analysis based on the variation in gene expression across cells within individual cell 
lines and PDX models. Following the Seurat pipeline27,28, we applied a principal component 
analysis on the top significant variable genes ranked by their normalized dispersion and 
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performed optimized K-means clustering on the PCs to categorize captured cells into distinct 
subpopulations, as described previously29. The identified subclusters were then visualized using t-
Distributed Stochastic Neighbor Embedding (tSNE)30 with cells partitioning into 6 – 9 
subpopulations within each model (Fig. 3.1d,e; Supplementary Dataset 3.2). Notably, we 
observed co-existing subpopulations present within each sample tested revealing widespread 
heterogeneity at the transcript level in breast cancer. We then inferred copy number variations 
(CNV)31 called using these data to determine the degree to which transcriptionally distinct 
subpopulations could be attributed to changes in clonality as measured by CNV levels 
(Supplementary Fig. 3.2). Ongoing analyses show multiple genetic subclones are present within 
subpopulations identified using expression-based clustering and hence, some but not all 
variability between cancer cells can be attributed to subclonality. 
 
3.3.2 Modular analysis of individual cells informs functional heterogeneity and 
mirrors inter-patient variability  
Having observed extensive heterogeneity at the single-cell level across the breast cancer models 
we profiled, we next sought to characterize this variability in terms of molecular mechanisms and 
function in addition to impacts on therapeutic response. To do so, we developed a new approach 
using a Modular Drug Response Prediction Pipeline (MODRx) in order to systematically 
discover drug combinations capable of counteracting tumor heterogeneity by predicting drug 
responses of individual breast cancer cells (Fig. 3.2a). We began by performing an in-depth 
molecular characterization of the luminal ER+ MCF7 cell line to study the extent that various 
subpopulations exist in different functional states. An unbiased analysis of gene expression 
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profiles of individual MCF7ER+ cells identified 7 subpopulations present within the bulk 
population (Fig. 3.2b). Of these subclusters, cells contained within Cluster 7 constituted the 
smallest fraction of the bulk population (5.36%) leading us to question if this rare group of cells 
was functionally distinct from the remaining tumor population. Interestingly, gene set 
enrichment analysis (GSEA) of the differentially expressed genes from cells identified in Cluster 
7 showed a significant enrichment for genes upregulated in basal mammary epithelial cells32–34 
which was surprising given that MCF7 cells are a luminal ER+ model of breast cancer (P < 
0.001, Fig. 3.2c, Supplementary Dataset 3.3). Furthermore, there was an increased frequency of 
cells in Cluster 7 positive for basal candidate markers (e.g. KRT17+, KRT16+) and negative for 
luminal markers (e.g. KRT18-, KRT19-) suggesting the presence of a basal-like subgroup of 
cells within this bulk population (Fig. 3.2d).  
 
Differences in gene expression measured from a bulk tumor sample could be due to differences in 
cell type composition ratios, a version of Simpson’s paradox35. We therefore hypothesized that 
using molecular signatures which are variable between patients could aid in the interpretation of 
differences between single cancer cells. For this purpose we used expression signatures reflective 
of between-patient heterogeneity in terms of breast cancer subtype36, and gene modules 
capturing patient variability derived from a cohort of 342 breast cancer patients37. Scoring 
individual MCF7ER+ cells based on their PAM50 gene signature reflected cells with differences 
in annotated subtype. These differences were also reflected in the single cell expression of gene 
modules annotated to represent differences in molecular programs present in bulk breast cancer 
samples (e.g. proliferation, ESR1/ER+, ERBB2/HER2, basal, epithelial-to-mesenchymal 
transition/EMT programs) (Fig. 3.2e, Supplementary Dataset 3.4). While we found that ESR1 
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module gene expression was evenly distributed across all MCF7 subpopulations, the basal 
module gene signature was distinctly elevated in cells specific to Cluster 7 (Fig. 3.2e,f). Taken 
together, our results indicate the presence of a basal-like subpopulation in an established luminal 
breast cancer cell line. 
 
We next investigated the degree of functional heterogeneity within another subtype of breast 
cancer by performing a similar characterization of cells from the HER2-amplified cell line 
SKBR3HER2 (Fig. 3.3a). While expression of ERBB2 and the ERBB2/HER2 module was 
consistent across all SKBR3HER2 subpopulations (Fig. 3.3b,c), we identified a small group of cells 
(6.03% of bulk population) comprising Cluster 8 that had a significantly higher frequency of cells 
positive for EMT markers CD44 and FN1 (Fig. 3.3d). Assessing individual cells based on 
expression of EMT module genes showed a rare population of cells specific to Cluster 8 were 
highly enriched for this program, consistent with the increased frequency of EMT candidate 
markers at the single gene level (Fig. 3.3e). Previous studies have shown EMT status can alter 
drug responses and has been associated with resistance to targeted therapies including HER2 
inhibitors38,39. In line with these reports, we found that breast cancer cell lines40,41 with a high 
expression of EMT module genes were significantly more resistant to the dual HER2/EGFR 
inhibitor lapatinib (Supplementary Fig. 3.3). As such, we hypothesized that the rare 
subpopulation of EMT module-high expressing cells observed within the SKBR3HER2 cell line 
may show similar patterns of resistance when treated with lapatinib, despite their HER2 status. 
To test this hypothesis, we developed a single-live-cell tracking workflow to directly assess the 
responses of different subpopulations to drug treatment through a competition assay established 
within a single model system (Fig. 3.3f, Supplementary Fig. 3.4). Using CD44 as a marker to 
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isolate EMT-high cells, bulk SKBR3HER2 cells were separated into CD44hi (top 5%) and CD44lo 
(remaining) subpopulations using fluorescence-activated cell sorting (FACS). To track the 
proliferation of CD44hi and CD44lo cells once they are mixed back into a single population, 
CD44hi cells were labeled with a red cell stain, which was stable over multiple cell divisions 
throughout a 96 h timeframe (Supplementary Fig. 3.4). In this competition assay following 72 h 
of lapatinib treatment, we observed higher relative proliferation and decreased apoptosis in 
CD44hi cells compared to the CD44lo fraction (Fig. 3.3g-i). Hence, using single-cell RNAseq we 
identified a subpopulation of pre-existing mesenchymal cells within the HER2-amplified 
SKBR3 cell line that display intrinsic resistance to HER2 inhibition.  
 
 3.3.3 A subpopulation of cells in an interferon-stimulated gene (ISG)-state is 
recurrent across TNBCs and associates with worse prognosis  
We next sought to characterize the cellular variability in various models of TNBC.  Surprisingly, 
analysis of gene expression profiles from the cells of two TNBC cell lines (HCC38, MDA-MB-
231) and a patient-derived xenograft model of TNBC (HCI-002) identified a small 
subpopulation enriched for genes involved in interferon signaling present in every model tested 
(HCC38: Cluster 6, 3.86%; MDA-MB-231: Cluster 5, 2.92%; HCI-002: Cluster 1, 37.9%) 
(Fig. 3.4a). Analysis of the top 50 differentially expressed genes from these subpopulations 
showed a significant enrichment for genes and gene sets involved in interferon signaling and viral 
processes, including selective enrichment for interferon responsive genes (IFIT1, IFIT2 and 
IFIT3) and genes involved in antigen presentation (HLA-A, HLA-B, and HLA-C) in HCC38 
Cluster 6 cells (Fig. 3.4b,c). Previous work in our lab identified a similar molecular program 
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representing an immune-like gene set involving many of these genes from breast cancer patient 
samples37 (Supplementary Fig. 3.5). Independent studies have also identified many of these genes 
as a co-expression module in a separate breast cancer cohort42,43. Scoring of individual HCC38 
and MDA-MB-231 cells showed Cluster 6 and Cluster 5 cells were highly enriched for the ISG 
module signature, respectively (Fig. 3.4d,e). Looking at the transcript profiles of breast cancer 
samples from The Cancer Genome Atlas44 (TCGA, n = 342 samples with full data) showed 
variable expression of ISG module genes across patients, which was similar in structure to the 
variability observed between individual TNBC cells (Fig. 3.4f,g). Furthermore, there was no 
enrichment for ISG module genes seen across any subclusters of SKBR3HER2 or MCF7ER+ cells 
(Fig. 3.4h). Analysis of individual patient samples from the METABRIC breast cancer cohort45 
(n = 1,966 samples) showed a significant enrichment for ISG genes specific to TNBC patients 
compared to those classified as receptor positive suggesting this phenomenon is specific to the 
TNBC subtype (Fig. 3.4i). Importantly, survival analysis of TNBC patients from the 
METABRIC cohort revealed that this recurrent ISG signature associates with a worse 
prognosis, suggesting patients with a high proportion of cells in this ISG-state may benefit from 
eradication of this subpopulation (Fig. 3.4j).   
 
3.3.4 ISG-state cells display heightened STING-pathway activation and genomic 
instability  
We next investigated the potential mechanisms underlying the presence of a recurrent 
subpopulation of ISG-cells in TNBCs. Previous work has shown that sustained expression of 
ISG genes can result from chronic cGAS/STING-pathway activation42,46 (Fig. 3.5a). One 
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potential route of STING-pathway activation can be attributed in response to cytosolic DNA 
fragments, whereby cGAS surveillance of micronuclei links genome instability to innate 
immunity through TBK1 signaling leading to ISG gene expression47. Additionally, the RNA 
sensing RIG-I/MAVS signaling pathway also converges on TBK1 and can serve as an alternate 
route to expressing ISG genes48–50 (Fig. 3.5a). Given that TNBCs are known to have higher 
levels of genomic instability44,51–54, we therefore hypothesized that the recurrent subpopulations 
observed in TNBC may be a result of an ISG-state caused by chronic cGAS/STING activation. 
Expression of STING (TMEM173) and STING effector genes (IRF3, ISG15, CCL5) was 
elevated in HCC38 cells in Cluster 6, which was previously identified as an ISG-module high 
subpopulation (Fig. 3.5b, 3.4d). Leveraging the fact that hyperactive ISG signaling leads to 
upregulation of antigen presentation machinery on the cell surface52, we isolated this 
subpopulation based on expression of HLA-A/B/C proteins using FACS and found HLAhi cells 
had increased amounts of total and phosphorylated TBK1 protein, confirming heightened 
STING-pathway activation in this group of cells (Fig. 3.5c, Supplementary Fig. 3.6). 
Furthermore, analysis of the dynamics of the HLA subpopulations revealed these cells exist in a 
transient state (Supplementary Fig. 3.6). We next sought to delineate the cause of activation of 
this pathway, which could be due to interferon stimulation, viral infection or genomic 
instability46. TNBCs have been previously shown to have increased amounts of genomic 
instability44,51–54 which can in theory lead to increased amounts of cytosolic DNA and subsequent 
activation of STING signaling. We observed a higher number of micronuclei formation in 
HCC38 HLAhi cells compared to the HLAlo subpopulation, suggesting genomic instability as 
the potential source of STING-pathway activation in these cells (Fig. 3.5d). Additionally, 
HCC38 cells identified in the ISG-state showed increased copy number variations again 
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pointing towards genomic instability as a potential cause of heightened STING-pathway activity 
and subsequent ISG expression (Supplementary Fig. 3.7).  
 
3.3.5 TNBC cells in the ISG-state are chemoresistant  
Since patients with high expression of an ISG signature were associated with worse prognosis 
(Fig. 3.4j), we next investigated the functional consequence a subpopulation of cells in the ISG-
state may have on treatment responses. In order to predict the response of these cells to therapy, 
we performed pharmacogenomics modeling based on bulk breast cancer cell line drug 
sensitivities. First, a panel of 82 molecularly characterized breast cancer cell lines40,41 were scored 
based on their ISG-module gene expression. Drug response data covering 90 compounds for 
these cell lines was then correlated with ISG module scores to identify compounds associated 
with sensitivity and resistance in the bulk breast cancer cell lines (Fig. 3.6a). We found that cell 
lines with high ISG module scores were significantly associated with resistance to the 
chemotherapies gemcitabine (r = -0.4244, P = 0.0079) and doxorubicin (r = -0.3054, P = 0.05) 
(Fig. 3.6b). We therefore predicted that subpopulations of ISG cells would show similar patterns 
of chemoresistance, and tested this using our single-live-cell tracking workflow to assess the 
sensitivities of HCC38 HLAhi (top 5%) and HLAlo (remaining) subpopulations in response to 
chemotherapy (Supplementary Fig. 3.8). As predicted, HCC38 HLAhi cells were resistant to 
gemcitabine compared to HLAlo cells as evidenced by increased proliferation, decreased 
apoptosis, and an increase in fraction of HLAhi cells in the remaining population following a 72 
h drug treatment (Fig. 3.6c-e). We observed a similar decrease in sensitivity in HCC38 HLAhi 
compared to the HLAlo subpopulation following treatment with doxorubicin confirming cells in 
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a ISG-state are resistant to these two chemotherapies (Fig. 3.6f-h). Furthermore, we confirmed 
a subpopulation of ISG cells in a second model of TNBC (MDA-MB-231) also had increased 
survival in response to gemcitabine and doxorubicin following long-term drug treatment 
(Supplementary Fig. 3.9). Consistent with our model, several studies have identified interferon-
related gene signatures upregulated upon drug resistance and in models of residual disease in 
breast cancer14,48,55,56 which may occur due to selection for this population by chemotherapy as we 
observed in vitro.    
 
3.3.6 Eliminating chemoresistant subpopulations by targeting tumor cells in an 
ISG-state with CDK4 or mTOR inhibitors  
We next asked if we could target this chemoresistant subpopulation of chronically inflamed 
TNBC cells using the predictions made from our pharmacogenomic modeling of bulk breast 
cancer cell line data. Our analysis identified cells in an ISG-state as hypersensitive to CDK4 
inhibitor fascaplysin and the mTOR inhibitor rapamycin suggesting a potential mode to target 
this chemoresistant subpopulation pharmacologically (Fig. 3.6a). We confirmed this effect in 
vitro by isolating HLAhi and HLAlo subpopulations of HCC38 cells and found decreased 
survival of HLAhi cells in response to long term treatment with palbociclib (CDK4i), ribociclib 
(CDK4/6i) and everolimus (mTORi) (Fig. 3.7a-c). Notably, whereas single-agent gemcitabine 
treatment could not robustly induce cell death in HLAhi cells, the addition of palbociclib in 
combination showed an increase in cell death on both subpopulations suggesting a potential 
strategy for targeting the full tumor cell population (Fig. 3.7d-f). Supporting this, analysis of 
subpopulations within a single mixed model of HCC38 cells showed single-agent gemcitabine or 
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palbociclib selectively induced apoptosis in HLAlo or HLAhi cells respectively, while combination 
treatment resulted in increased cell death in both subpopulations (Fig. 3.7g). Together this data 
suggests targeting TNBC cells in an ISG-state with palbociclib can increase the efficacy of 
chemotherapy treatments by eradicating a resistant subpopulation leading to increased 
elimination of the full tumor landscape.  
 
 
3.4 Discussion  
 
Through pharmacogenomic modeling based on bulk cancer cell line drug sensitivities, we 
developed a new approach using a Modular Drug Response Prediction Pipeline (MODRx) in 
order to systematically discover drug combinations capable of counteracting tumor heterogeneity 
by predicting drug responses of individual breast cancer cells. Analysis of single-cell profiles from 
breast cancer cell lines and patient-derived xenograft models in conjunction with data from 
patient tumor samples revealed a high magnitude of heterogeneity both across different lineages 
and within each model system analyzed. Inference of CNV levels of individual cells showed 
multiple genetic subclones are present within transcriptionally distinct subpopulations, 
corroborating external reports showing some but not all variability between cancer cells can be 
attributed to subclonality9,24. 
 
We reasoned that the molecular variability between individual breast cancer cells and subsequent 
impact on drug sensitivities could be modeled by taking an unbiased modular analysis approach 
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that incorporates differences observed between breast cancer patients and may better capture and 
explain the heterogeneity seen between cells. In doing so, we identified a rare subpopulation of 
basal-like cells within the MCF7 ER+ cell line, in line with previous studies showing breast 
cancer cell lines are populated by cells coexisting in numerous differentiation-states with distinct 
luminal, basal, and mesenchymal gene expression patterns leading to heterogeneity in these 
model systems16,57. This finding has severe clinical implications in that targeted therapies have 
been shown to enrich for distinct differentiation states in breast cancers. For example, treatment 
with the MEK inhibitor trametinib has been shown to enrich for breast cancer cells in a 
basoluminal (K19/K5/K14-high, K8/VIM-low) state suggesting target therapies have different 
impacts on cell lineages and drug combinations are required to reduce therapeutic escape16. 
Building on this, we developed a computational approach to identify signatures of drug 
resistance and sensitivity of individual cells based on bulk cell line pharmacologic profiling 
datasets and patient-derived gene modules and applied this approach in the context of the 
HER2-amplified cell line SKBR3. We identified a subgroup of pre-existing mesenchymal cells 
within the SKBR3 population that displayed intrinsic resistance to lapatinib which we 
experimentally validated using a single-live-cell tracking workflow.  
 
Our data identified a recurrent subpopulation of cells in an ISG-state that was specific to TNBC 
cells and displayed heightened STING-pathway activation and genomic instability. By applying 
our MODRx approach we determined these cells are associated with chemoresistance and poor 
outcome in TNBC patients. This finding is aligned with previous studies defining interferon-
related gene signatures upregulated upon drug resistance and potentially explains the cellular 
source of heightened ISG expression found in residual TNBC tumors after 
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chemotherapy14,48,55,56. Furthermore, our analysis predicted ISG-state cells as hypersensitive to 
CDK4/6 and mTOR inhibition, which we validated as an effective strategy for targeting this 
chemoresistant subpopulation in TNBC. Guided by our in silico modeling and single-cell 
predictions, we show the addition of palbociclib to gemcitabine or doxorubicin treatment is an 
effective strategy for increasing therapeutic efficacy on TNBC tumor landscapes in their entirety.  
 
By taking a modular approach to assessing breast cancer heterogeneity we were able to 
characterize molecular and functional differences between transcriptionally distinct subsets of 
cells and ultimately link tumor transcriptional heterogeneity with drug actionability. There were 
several reasons for approaching this study using MODRx: (1) ideal use-case for studying single-
cells in that aggregating genes into modules facilitates processing the high-dimensional data 
acquired from sequencing at the single-cell level; (2) using modules overcomes technical 
challenges associated with analyzing single-cell expression profiles due to sparsity in mRNA 
measurements and provides a method for detecting zero-inflated genes in single-cell 
transcriptomics data; (3) modules simplifies gene sets making analysis more computationally- 
and time-efficient; (4) gene modules are effective tools for connecting functional characteristics 
to individual cells in that they are representative of co-expression patterns in patients, provide 
pathway-enrichment insight, and can be correlated with drug response data from large-scale 
databases. This affords a useful tool for rapidly defining drug sensitivities and resistance patterns 
within tumors by bypassing the need for extensive functional screening of each independent 
subpopulation for candidate identification, and ultimately leading to quicker clinical translation.  
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Using in silico and experimental approaches, our study provides an effective new framework to 
discover drug combinations capable of counteracting tumor heterogeneity by predicting drug 
responses of individual breast cancer cells and systematically links tumor transcriptional 
heterogeneity with drug actionability to optimize therapy combinations. Ongoing efforts are 
currently underway to translate this approach at scale by developing a machine-learning model 
for generating a drug-by-cell matrix to provide a systematic method for predicting single-cell 
responses and inform candidate combination strategies. 
 
 
3.5 Methods  
 
3.5.1 Breast cancer cell lines and reagents 
SKBR3HER2 cells were obtained from the UCSF Cell Culture Facility. HCC38TNBC, MCF7ER+, 
and MDA-MB-231TNBC cell lines were obtained from the American Type Culture Collection 
(ATCC). Cell lines were grown according to published protocols58 except for SKBR3 cells, 
which were cultured using RPMI media supplemented with 10% fetal bovine serum (FBS) and 
1% pen/strep. All cell lines tested negative for mycoplasma contamination. Drugs used for cell 
culture experiments in this study were purchased from Selleck Chemicals (Gemcitabine, 
Doxorubicin, Ribociclib) and LC Laboratories (Palbociclib, Everolimus). 
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3.5.2 Patient-derived xenograft model and tissue dissociation 
The HCI-002PDX-TNBC patient-derived xenograft (PDX) tumor sample was flash frozen in liquid 
nitrogen following a previous study where tumors were grown as previously described59,60. Viable 
tumor sample was then thawed and dissociated for fluorescence-activated cell sorting (FACS) 
using established protocols61. Briefly, tissue was mechanically chopped with scalpels and placed 
in culture medium DMEM/F12 with 5% FBS, 5 µg ml−1 insulin (UCSF Cell Culture Facility), 
50 ng ml−1 gentamycin (UCSF Cell Culture Facility) and supplemented with 2 mg 
ml−1 collagenase-1 (Sigma). Sample was then digested for 45 min at 37 °C. The resulting 
suspensions were resuspended in 2 U µl−1 DNase (D4263-5VL, Sigma Aldrich) for 3 min at 
room temperature, washed and dissociated with 2 ml of 0.05% trypsin/EDTA (25-052-CI, 
Corning) for 10 min at 37 °C. Cell suspensions were then filtered through a 70 µm filter, and 
frozen in DMEM/F12 with 50% serum, 10% DMSO, and stored in liquid nitrogen prior to 
study. 
 
3.5.3 Single-cell RNA sequencing (scRNAseq) 
Breast cancer cell lines (MCF7ER+, SKBR3HER2, MDA-MB-231TNBC) were thawed and carried 
according to published culture methods as described. Viably frozen cell suspensions of PDX 
tumor sample (HCI-002PDX-TNBC) were thawed and washed using DMEM prior to FACS 
sorting. Cells were stained for FACS using fluorescently labeled antibodies for human antigen 
CD298 (PE; 341704, BioLegend) and mouse antigens CD45 (APC; 559864, BD Pharmingen), 
CD31 (APC; 551262, BD Pharmingen) and Ter119 (APC; 557909, BD Pharmingen). Flow 
sorting was done using a BD FACSAria II cell sorter (Becton Dickinson) where contaminating 
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hematopoietic and endothelial cells were excluded by gating out Lin+ (CD45, Ter119, CD31) 
cells, and dead cells were eliminated by excluding Sytox positive (SYTOX Blue Dead Cell Stain, 
S34857, Life Technologies) cells. Samples showing at least 80% viability as measured using 
SytoxBlue in FACS were proceeded with for single-cell sequencing. 
 
For droplet-enabled scRNAseq, flow cytometry sorted cells were washed in PBS with 0.04% 
BSA and resuspended at a concentration of ~1000 cells/µl. Single-cell RNA sequencing was 
performed under the supervision of the IHG Genomics Core (UCSF) using the Chromium 
Single Cell 3ʹ Reagents Kit (CG00026 Rev B., 10x Genomics), and libraries were prepared 
following the manufacturer’s protocol. Quantification of cDNA libraries was performed using 
Qubit dsDNA HS Assay Kit (Q32851, Life Technologies) and high-sensitivity DNA chips 
(5067-4626, Agilent). Libraries were then sequenced using the Illumina HiSeq2500 platform to 
achieve an average calculated depth of 50,000 reads per cell. 
 
3.5.4 scRNAseq data processing and analysis 
The Cell Ranger Single-Cell Software Suite v1.1.0 was used to perform sample demultiplexing, 
barcode processing and single-cell 3′ gene counting (http://software.10xgenomics.com/single-
cell/overview/welcome). For cluster identification in the scRNAseq datasets, we utilized the 
Seurat pipeline27,28,30. The data matrices were imported into R and processed initially with the 
Seurat R package version 2.0 and later with Seurat R package version 3.0, where the FPKM 
values were transformed into log-space after the aforementioned trimming steps (each gene was 
expressed in at least three cells, each cell has at least 200 genes). Principal component analysis 
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(PCA) was performed using highly variable genes for each separate sample in the trimmed 
dataset. Using significant principal components (determined by Jackstraw method) as input, we 
then performed density clustering to identify groupings in the data and t-distributed statistical 
neighbor embedding (tSNE) to visualize. Marker genes for each respective cluster were 
identified and utilized in subsequent analysis using further Seurat functionality. 
 
3.5.5 Module scoring 
Molecular programs describing breast cancer biology and representing breast cancer patient 
variability were previously defined using MAGNETIC37. To compare the identified 219 gene 
signatures in subpopulations, gene module scores were calculated for each individual cell in order 
to evaluate the degree to which single-cells express a given module. Of note, cells with higher 
complexity would be expected to have higher cell scores for any set of genes analyzed. To account 
for this confounding effect, for each gene module analyzed, a control gene-set was created to be 
used in the calculation of a normalization factor as described previously62. Briefly, control gene 
sets were selected to ensure a similar distribution of expression levels to that of the input gene 
module. First, all genes analyzed are ordered by mean expression across all cells and partitioned 
into 25 bins of similar expression. Next, for each gene in the given gene module or signature, 5 
control genes were randomly selected from its corresponding expression bin and added to a 
control set. The resulting control set contained an equivalent expression distribution as the target 
gene module and its average represents an equivalent sampling of 100 gene sets of equal size to 
the target gene module. The expression of genes in the target gene module and the control gene 
set was averaged across each cell to generate a target score (𝑆!"#$%&) and control score (𝑆!"#$). 
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The cell’s score for the target gene module (𝑆!"#) is then the difference between the target score 
and control score: 𝑆!"# =  𝑆!"#$%& −  𝑆!"#$.  
 
3.5.6 Gene Set Enrichment Analysis (GSEA) 
Gene set enrichment analysis (GSEA) of hallmark cancer gene signatures in the Molecular 
Signatures Database (MSigDB v6.0) was performed using GSEA v3.0 software 
(http://www.broadinstitute.org/gsea/)33,34 under the following parameters: permutation, 
phenotype; metric, Signal2Noise; scoring scheme, weighted; and number of permutations, 1,000. 
Gene sets were considered significantly enriched following a nominal P < 0.05 and FDR < 0.25 
cutoff. Cells belonging to subpopulations were averaged to serve as a representation of each 
subgroup, and trimmed to their respective marker genes as determined by Seurat following log 
transformation. 
 
3.5.7 Fluorescence-activated cell sorting (FACS) of subpopulations 
Excluding FACS analysis prior to sequencing as described above, sorting of SKBR3, HCC38, 
and MDA-MB-231 cells was performed on a Sony SH800S Cell Sorter (Sony) using the 
following fluorochrome-conjugated antibodies at the manufacturer’s recommended 
concentration unless otherwise indicated: anti-human CD44 conjugated to APC-H7 (560532, 
BD Pharmingen) at 1:200, and anti-human HLA-A/B/C conjugated to Alexa Fluor® 488 
(560169, BD Pharmingen). Gating of positive and negative cells was defined by the unstained 
control, and cells were sorted into representative high and low expressing populations as 
indicated. For ISG module kinetics experiments, HCC38 cells of each subpopulation 
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(ISG/HLAhi: top 5%; ISG/HLAlo: bottom 10%, control sort: bulk HCC38) were sorted and 
reanalyzed by FACS immediately post-sorting and at 14 d afterwards. Final analysis was 
performed using FlowJo Software v10.6.1 (Tree Star). 
 
3.5.8 Single-live-cell tracking 
We developed a single-live cell tracking workflow to directly assess the functional implications of 
various subpopulations of cancer cells within a heterogeneous mixed-model system. First, 
subpopulations of interest were isolated using FACS as previously described. Following sorting, 
we then labeled the cytoplasm of living cells from subpopulations of interest using the IncuCyte® 
CytoLight Rapid Red Reagent (4706, Essen BioScience) per the manufacturer’s protocol, while 
additional subpopulations were left unlabeled. This stably fluorescent dye freely passes through 
cell membranes and transforms into a cell-impermeant fluorescent probe that is transferred by 
dilution to daughter cells without affecting adjacent cells within a population, allowing for 
tracking subpopulations of cells over time without perturbing cell function or biology. Reagent 
concentration was independently optimized in all breast cancer cell lines used in the study to 
determine fluor stability duration and detection limits for monitoring cells in mixed cultures. 
IncuCyte® Caspase-3/7 Green Reagent (4440, Essen BioScience) or YO-PRO-1 (Thermo 
Fisher Scientific) was multiplexed with the tracking reagent to simultaneously determine 
apoptotic or cytotoxic effects within wells. Both labeled and unlabeled subpopulations of cells 
were then mixed back into a homogenous system and seeded in 384-well assay microplates and 
allowed to adhere over 8 h. Cells were then treated with drug and imaged over 72 h at 2 h 
timepoints using the IncuCyte® S3 Live-Cell Analysis System with a Green/Red Optical 
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Module. Capturing images from phase, green, and red channels allowed for monitoring 
unlabeled cells, apoptotic cells, and labeled subpopulations respectively. 
 
3.5.9 Drug sensitivity studies 
Cells were seeded in 384-well assay microplates at a density of 1,000 cells/well in a total volume 
of 40 µL/well and incubated at 37°C, 5% CO2 overnight. Following 72 h drug exposure, 
proliferation and cell death was measured by staining with Hoechst 33342 (Thermo Fisher 
Scientific) nuclear dye and YO-PRO-1 (Thermo Fisher Scientific) early apoptosis dye, 
respectively. Stained plates were then analyzed using a CellInsight High Content microscope 
(Thermo Fisher Scientific). Raw phenotype measurements from each treated well were 
normalized to the median of vehicle-treated control wells and examined for response. 
 
3.5.10 Colony formation assay 
Colony formation assays were performed using crystal violet staining and quantification. Briefly, 
cells were seeded in 12-well microplates at a density of 1,000 cells/well and incubated at 37°C, 
5% CO2 overnight. Cells were then exposed to drug or DMSO vehicle for 10-14 d, with 
medium change and drug refresh every 3 d. Cells were fixed with 4% formaldehyde and stained 
with 0.5% crystal violet. Images of stained cells were taken using an EPSON Perfection V600 
scanner prior to quantification. Growth was quantified by dissolving crystal violet in 0.1% SDS 
and absorbance was measured at 590 nm using a spectrophotometer and normalized to vehicle-
treated controls. 
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3.5.11 Immunoblot 
Subpopulations of cells were collected via FACS and proteins were extracted using RIPA buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% sodium deoxycholate, 0.1% SDS, 1 mM 
EDTA pH 8.0, 1% NP-40) supplemented with protease and phosphatase inhibitor cocktails 
(Roche). Samples were sonicated and then centrifuged at 14,000 r.p.m. for 15 min at 4°C. 
Protein concentrations were determined by Bradford assay (Bio-Rad). Equal amounts of protein 
samples were resolved using 4–12% SDS-PAGE gels (Life Technologies) and transferred to 
polyvinylidene difluoride membranes (Millipore). Membranes were probed overnight on a 4°C 
shaker with primary antibodies (1:1,000 dilution unless indicated) recognizing the following 
proteins: p-TBK1 (Ser172) (5483, Cell Signaling), TBK1 (3504, Cell Signaling), cGAS (15102, 
Cell Signaling), p-S6 (Ser240/244) (5364, Cell Signaling, 1:20,000), p-4E-BP1 (Thr37/46) 
(2855, Cell Signaling), p-STAT1 (Tyr701) (9167, Cell Signaling), MYC (ab32072, Abcam), 
and β-actin (3700, Cell Signaling). Proteins were detected via incubation with horseradish 
peroxidase-conjugated secondary antibodies, Clarity Western ECL Blotting Substrates (Bio-
Rad) or SuperSignal West Femto Maximum Sensitivity Chemiluminescent Substrate (Thermo 
Fisher Scientific). 
 
3.5.12 Immunofluorescence 
After sorting subpopulations via FACS, cells were grown on glass coverslips and fixed with 4% 
paraformaldehyde (PFA) in PBS for 10 min at room temperature. Cells were then permeabilized 
in 1X PBS/0.3% Triton X-100 for 10 min at room temperature before blocking for 40 min with 
3% BSA in PBS. Coverslips were then incubated with primary antibody overnight at 4°C, 
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followed by incubation with a secondary antibody for 1h at room temperature. Both primary and 
secondary antibodies were diluted in blocking buffer given the following dilutions: cGAS 
(D1D3G) (Cell Signaling, 1:200), anti-rabbit-Alexa 488 (A11008) (Invitrogen, 1:1,000). 
Coverslips were then mounted using Vectashield Antifade Mounting Medium with DAPI (H-
1200, Vector Laboratories) and imaged using a Zeiss LSM 780 confocal microscope with 25× 
and 63× objectives. The images were further processed in ImageJ and scoring was performed 
under blinded conditions. 
 
3.5.13 Quantification of micronuclei frequency 
After fixation and DAPI staining, cells containing micronuclei were visualized by microscopy 
using a confocal microscope (Zeiss LSM 780) equipped with a 25× and 63× water immersion 
objective and a CCD camera. Cells were analyzed under blinded conditions and micronuclei 
positive fractions calculated as a percentage of total cells per field. For quantification, multiple 
(3-5) random fields were captured and 700-1000 cells were counted in each independent 
experiment. Micronuclei were defined as discrete DNA aggregates separate from the primary 
nucleus in cells where interphase primary nuclear morphology was normal. Cells displaying 
mitotic morphology and/or with an apoptotic appearance were excluded. 
 
3.5.14 CNV estimation based on single-cell RNAseq data 
Large-scale copy number variations (CNVs) were inferred from single-cell expression data using 
the InferCNV algorithm31. Initial CNVs were estimated by sorting the analyzed genes by their 
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chromosomal location and applying a moving average to the relative expression values, with a 
sliding window of 100 genes within each chromosome, as previously described63. 
 
3.5.15 Statistical analysis 
Data are expressed as means ± s.d., unless otherwise indicated. Statistical analyses were 
performed using GraphPad Prism 6 (v6.0g) and R (v3.4.4). Two-tailed Student t-tests (with 
unequal variance) were used in all comparisons unless otherwise noted. P < 0.05 was considered 
statistically significant throughout the study. 
 
3.5.16 Data availability statement 
All data generated or analyzed during this study are included in this published article and its 
supplementary information files. 
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3.8 Figures  
 
Figure 3.1 Single-cell RNAseq across multiple models of breast cancer. (a) Schematic of single-
cell profiling approach. (b) Combined UMAP projection of cells from various breast cancer cell 
lines representing different ER+, HER2-amplified, and TNBC subtypes. Individual cells are 
colored based on cell line identity. (c) UMAP projection of cells from a cohort of 8 TNBC 
patients9 Individual cells are colored based on patient identity. (d) tSNE map of cells from breast 
cancer cell lines. (e) tSNE map of cells from a patient-derived xenograft model of TNBC (HCI-
002PDX-TNBC). For (d,e) individual cells are colored by clusters identified using independent 
graph-based clustering analysis for each model tested. BCCL, breast cancer cell line; TNBC, 
triple-negative breast cancer; PDX, patient-derived xenograft. 
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Figure 3.2 Modular analysis of individual breast cancer cells informs functional heterogeneity 
and mirrors inter-patient variability. (a) Schematic for designing rational combination strategies 
using a Modular Drug Response Prediction Pipeline (MODRx). (b) tSNE plot showing 
subclusters of cells identified within a MCF7ER+ bulk population. (c) Gene set enrichment 
analysis (GSEA) of transcript profiles from MCF7ER+ cells identified in Cluster 7 compared to 
non-Cluster 7 cells. (d) Frequency of MCF7ER+ cells negative for luminal markers (KRT18, 
KRT19; top) and positive for basal markers (KRT17, KRT16; bottom) as a percentage of all 
cells within each subcluster. (e) Relative module score for known molecular breast cancer 
programs (proliferation, ESR1/ER, ERBB2/HER2, basal, EMT) of individual MCF7ER+ cells 
within subclusters. Gene module expression for individual cells mapped onto tSNE plots are 
shown below. (f) Average expression and percentage of cells expressing ESR1/ER and basal 
module genes for each subcluster of MCF7ER+ cells.  
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Figure 3.3 A subpopulation of pre-existing mesenchymal cells within the SKBR3HER2 cell line 
display intrinsic resistance to lapatinib. (a) tSNE plot showing subclusters of cells identified 
within a SKBR3HER2 bulk population, highlighting Cluster 8. (b) ERBB2 expression levels for 
individual SKBR3HER2 cells. (c) Relative ERBB2/HER2 module score for individual SKBR3HER2 
cells. (d) Frequency of SKBR3HER2 cells positive for markers of EMT (CD44, left panel; FN1, 
right panel). P values calculated using one-way ANOVA. (e) Relative EMT module score for 
individual SKBR3HER2 cells. (f) Single-live-cell tracking workflow scheme. (g) Relative 
proliferation of CD44lo (unlabeled) and CD44hi (red) SKBR3 cells following 72 h treatment with 
5 µM lapatinib. Data represents n = 4 biologically independent samples. Error bars are mean ± 
s.d., and P values calculated using a two-sided t-test. (h) Fold change apoptotic cells following 
72 h lapatinib treatment for CD44lo and CD44hi SKBR3 cells. Data represents n = 4 biologically 
independent samples. Error bars are mean ± s.d. (i) Representative images of SKBR3 
subpopulations (CD44lo, unlabeled; CD44hi, red) after 72 h treatment with 80 nM lapatinib 
showing selective cell death in CD44lo cells. Dead cells are labeled green. Images are shown 
using a 10× objective. Scale bars, 50 µm. 
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Figure 3.4 A subpopulation of cells in an interferon-stimulated gene (ISG)-state is recurrent in 
TNBCs. (a) tSNE plots for individual cells from two TNBC cell lines (HCC38, MDA-MB-
231) and a patient-derived xenograft model of TNBC (HCI-002) highlighting clusters enriched 
for ISG genes. Heatmaps displaying scaled expression patterns of top marker genes within each 
cluster shown to the right with ISG genes highlighted (yellow indicates high, and purple 
indicates low). Percentage of cells contained in each identified cluster is listed at the top. (b) 
Significantly enriched gene sets identified from a Gene Set Enrichment Analysis (GSEA) of the 
top 50 differentially expressed genes from HCC38 Cluster 6, MDA-MB-231 Cluster 5, and 
HCI-002 Cluster 1 cells. (c) Expression levels of various interferon genes for individual HCC38 
cells. Relative ISG-module scores for individual (d) HCC38 and (e) MDA-MB-231 cells. Insert 
shows ISG-module expression for individual cells mapped onto tSNE plots. (f) Relative 
expression levels for ISG-module genes across breast cancer patients from the TCGA. Patients 
sorted based on ISG-module score. (g) Relative expression levels for ISG-module genes across 
individual HCC38 cells. Cells are sorted based on cluster identity listed above. (h) Relative ISG-
module scores for individual SKBR3HER2 (left) and MCF7ER+ (right) cells. (i) Normalized gene 
expression levels for ISG genes comparing TNBC and receptor positive breast cancer patients 
from METABRIC data. Box-and-whisker plots show median (centerline), upper/lower quartiles 
(box limits), and whiskers spanning the interquartile range from 25-75 percentiles. P value 
calculated using a two-sided t-test. (j) Kaplan-Meier survival curves of TNBC METABRIC 
samples stratified based on IFN gene signature status. P value calculated using a log-rank test. 
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Figure 3.5 ISG-state cells display heightened STING-pathway activation and genomic 
instability. (a) cGAS/STING signaling pathway model. (b) Expression levels of various STING 
effector genes for individual HCC38TNBC cells based on cluster identity. (c) HCC38 cells were 
sorted into HLAhi (top 5%) and HLAlo (remaining) populations by FACS, and protein lysates 
were subjected to immunoblot using the indicated antibodies. Representative image from n = 3 
independent experiments. (d) Representative images of HCC38 HLAlo (top) and HLAhi 
(bottom) subpopulations with DAPI (blue) staining DNA. Arrows indicate micronuclei positive 
cells. Higher magnification of HCC38 HLAhi cells positive for micronuclei shown to the right. 
Percentage of cells positive for micronuclei is quantified at the right. Data is an average of five 
high-powered (25×) fields (≥150 cells/field) analyzed per subpopulation. Error bars are mean ± 
s.d., and P value calculated using a two-sided t-test. Images are shown using a 25× objective. 
Scale bars, 20 µm unless indicated otherwise.  
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Figure 3.6 TNBC cells in the ISG-state are chemoresistant. (a) ISG-module scores from a panel 
of 82 breast cancer cell lines were correlated with drug response values across 90 compounds. 
Pearson correlation values shown. (b) Scatter plot of breast cancer cell line ISG-module scores 
associated with gemcitabine (left panel; r = -0.4244, P = 0.0079) and doxorubicin (right panel; r = 
-0.3054, P = 0.05) sensitivities. P values based on Pearson correlations. (c) Proliferation of 
HCC38 HLAlo, HLAhi, and mixed-bulk populations in response to 72 h gemcitabine treatment. 
IC50 quantification of dose-response curves shown at the right. (d) Fold change apoptotic 
HCC38 cells for HLA subpopulations after 72 h treatment with 5 nM gemcitabine. (e) Fraction 
of remaining cell population consisting of HLAlo and HLAhi HCC38 cells after 72 h 
gemcitabine treatment. (f) Proliferation of HCC38 HLAlo, HLAhi, and mixed-bulk populations 
in response to 72 h doxorubicin treatment. Emax quantification of dose-response curves shown 
at the right. (g) Fold change apoptotic HCC38 cells for HLA subpopulations after 72 h 
treatment with 15.6 nM doxorubicin. (h) Fraction of remaining cell population consisting of 
HLAlo and HLAhi HCC38 cells after 72 h doxorubicin treatment. For (c-h), data represents n = 
4 biologically independent samples. Error bars are mean ± s.e.m., and P values calculated using a 
two-sided t-test.  
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Figure 3.7 Targeting a subpopulation of cells in an ISG-state with CDK4 or mTOR inhibitors 
increases efficacy of chemotherapies on the full tumor landscape. Crystal violet staining of 
HLAlo and HLAhi HCC38 cells after 14 d treatment with increasing concentrations of (a) 
palbociclib (CDK4i), (b) ribociclib (CDK4/6i), and (c) everolimus (mTORi). Representative 
images of n = 2 independent experiments with similar results, and quantification of dye shown 
below. Fold change apoptotic cells for HCC38 HLA subpopulations after 72 h treatment with 
(d) single-agent gemcitabine or (e) in combination with 0.5 µM palbociclib. Combinations were 
normalized to palbociclib alone. (f) Schematic showing drugs acting on distinct subpopulations 
of cells. (g) Representative images showing 10 nM gemcitabine inducing cell death in HCC38 
HLAlo cells (top), 0.5 µM palbociclib inducing cell death in HCC38 HLAhi cells (middle), and 
the combination of the two agents resulting in cell death in both subpopulations (bottom). 
Arrows indicate YO-PRO-1-positive (dead) cells. Quantification shown to the right. In all 
graphs, data represents n = 4 independent samples, error bars are mean ± s.d., and P values 
calculated using a two-sided t-test unless stated otherwise. 
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3.9 Supplementary Figures  
 
 
Supplementary Figure 3.1 Methods for measuring cell-cell similarity and clustering. (a) 
Hierarchical clustering of MCF7 (ER+), SKBR3 (HER2) and MDA-MB-231 (TNBC) cells 
from single-cell RNAseq profiling data is shown. Dendogram was constructed using Ward 
Linkage with squared Euclidean distance as the unit of measure between points. Individual cells 
are annotated based on parent cell line identity shown below. (b) K-means clustering result for 
individual breast cancer cells. Individual cells fall into three dominant clusters and are annotated 
based on parent cell line identity as in panel (a). BCCLs, breast cancer cell lines.   
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Supplementary Figure 3.2 Interpreting expression-based subpopulations of HCC38 cells using 
CNV estimations. (a) Chromosomal landscape of inferred large-scale CNVs for HCC38 cells as 
an output from running InferCNV31 Individual HCC38 cells (y axis) and chromosomal regions 
(x axis) are shown with amplifications (red) or deletions (blue) inferred by averaging expression 
over 100-gene stretches on the respective chromosomes. (b) Comparison of number of cells 
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within each subgroup identified using CNV-based and expression-based clustering approaches. 
(c) Enrichment plot showing expression-based clusters belong to multiple genetic subclones.    
(d) Frequency of CNV clusters present in each expression-based cluster of cells.    
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Supplementary Figure 3.3 EMT module status correlates with lapatinib sensitivity. A panel of 
82 breast cancer cell lines were scored based on EMT module status. Scatter plot shows EMT-
module scores negatively associate with lapatinib sensitivity based on –log10 GI50 values from 
published datasets (Heiser, et al., Daemen, et al.),40,41. The HER2-amplifed cell line SKBR3 is 
highlighted in red. P value based on Pearson correlation.  
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Supplementary Figure 3.4 Single-live-cell tracking optimization for SKBR3 cells. (a) Single-
live-cell tracking workflow scheme. Bulk SKBR3 cells are labeled with CD44 antibody. CD44hi 
and CD44lo subpopulations are isolated via FACS. CD44hi cells are stained red with 0.11 µM of 
CytoLight Rapid Red® reagent to track subpopulation over time. CD44lo cells are left unstained. 
CD44hi-red and CD44lo-unlabeled subpopulations are mixed back into single bulk model, 
treated with drug for 72 h, and imaged using time-lapse microscopy. (b) Proliferation of SKBR3 
cells over time following increasing concentrations of CytoLight Rapid Red® reagent. (c) 
Relative fraction of SKBR3 cells expressed as a percentage of control (DMSO) after 72 h 
staining with increasing concentrations of CytoLight Rapid Red®. For (b,c) data represents n = 4 
biologically independent samples and error bars are mean ± s.d. 
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Supplementary Figure 3.5 ISG signature overlap in TNBC cells. (a) Circos plot showing genes 
comprising the ISG module derived using the MAGNETIC algorithm (Webber, et al.)37. 
Linkages are colored based on edge source data type. (b) Overlap of genes involved in the ISG 
module identified in Webber, et al. in comparison to gene lists encompassing significant 
differentially expressed genes from HCC38 Cluster 6 and MDA-MB-231 Cluster 5 cells 
(relative to all other clusters). Genes overlapping in all three gene sets are shown below. (c) 
Overlap of genes identified in published ISG signatures (Webber, et al., Liu, et al.)37,42 in 
comparison to differentially expressed gene lists from HCC38 Cluster 6 and MDA-MB-231 
Cluster 5 cells. Relative ISG module scores using the Liu, et al. signature shown for individual 
(d) HCC38 and (e) MDA-MB-231 cells.   
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Supplementary Figure 3.6 HLA kinetics in HCC38 cells. (a) HLA-A, HLA-B, and HLA-C were 
compiled into a single gene module (HLA-A/B/C) and HCC38 cells were scored based on their 
expression of module genes. Violin plot of the relative gene module score for individual cells 
within each subcluster is shown. Top significantly differentially expressed gene lists from.         
(b) Isolation via FACS of HCC38 HLA-hi (top 5%) and HLA-lo (bottom 10%) populations. 
(c) Percentage of cells in each subpopulation identified as HLA-hi via FACS analysis 
immediately after sorting (0 d) and 14 d post initial sort. (d). HLA kinetics in various HCC38 
subpopulations is shown over 14 d. Pie charts depict relative proportions of HLA-hi (red) and 
HLA-lo (grey) subpopulations for an unsorted sample of HCC38 cells (left, initial distribution) 
and for sorted subpopulations (top, HLA-high; middle, HLA-lo; bottom, control bulk 
population) analyzed immediately after sorting (0 d) and 14 d post initial sort. Data represents n 
= 2 independent experiments.  
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Supplementary Figure 3.7 HCC38 ISG cells have heightened genomic instability as determined 
by CNV analysis. (a) Chromosome instability shown for HCC38 cells in each expression-based 
subpopulation compared to remaining clusters. P value calculated using a two-sided t-test. (b) 
Interferon-stimulated genes have significantly higher CNV levels in HCC38 cells in the ISG 
subpopulation (Cluster 6) compared to non-Cluster 6 cells. In all graphs, Box-and-whisker plots 
show median (centerline), upper/lower quartiles (box limits), and whiskers spanning the 
interquartile range from 25-75 percentiles. CNV, copy number variation. 
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Supplementary Figure 3.8 Single-live-cell tracking optimization for HCC38 cells. (a) 
Proliferation of HCC38 cells over time following increasing concentrations of CytoLight Rapid 
Red® reagent. (b) Red signal strength shown as percentage of positive cells with detectable signal 
at 48 and 72 h after staining with the indicated concentrations of CytoLight Rapid Red® 
reagent. (c) Fold change apoptotic cells following 48 and 72 h staining with increasing 
concentrations of CytoLight Rapid Red® reagent. All data represents n = 4 biologically 
independent samples and error bars are mean ± s.d. 
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Supplementary Figure 3.9 Subpopulations of TNBC cells in an ISG-state have increased long-
term survival in response to chemotherapies. (a) Crystal violet staining of HLAhi (top 5%) and 
HLAlo (remaining) HCC38 cells after 14 d treatment with increasing concentrations of 
gemcitabine. (b) Quantification of dye from images shown in panel (a). (c) Crystal violet staining 
of MDA-MB-231 HLAhi (top 5%) and HLAlo (remaining) subpopulations following 14 d 
treatment with 2 nM gemcitabine or 4 nM doxorubicin. (d) Quantification of dye from images 
shown in panel (c). Images are representative of n = 2 independent experiments with similar 
results. In all graphs, data represents n = 4 independent samples.  
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Chapter 4.  
Conclusions and future directions 
 
Here we developed two approaches towards designing novel combination strategies for 
overcoming drug resistance in breast cancer. First, using an unbiased chemoproteomics approach, 
we profiled kinome dynamics across breast cancer cells in response to various targeted therapies 
and identified signaling changes that correlate with drug sensitivity. This signaling map 
identified survival factors whose presence limits the efficacy of targeted therapies and revealed 
AURKA as a new co-targeting opportunity to enhance the therapeutic efficacy of PI3K-pathway 
inhibitors in breast cancer. The systematic measurement of kinome dynamics across a diverse set 
of cell lines allowed us to map molecular changes associated with resistance to a variety of 
inhibitors, which is unique from previous approaches limited to a single drug or cell line. We 
found a number of cases in which failure to inhibit a particular kinase was associated with drug 
resistance. As our proteomic screen included multiple drugs that impinge on distinct oncogenic 
pathways, we found it surprising that a set of common survival factors were identified. Future 
work may determine if other candidates we identified also act as survival factors and how they 
might do so. We also showed that MYC-driven AURKA activation results in maintenance of 
the PI3K-pathway despite PI3K inhibitor treatment, resulting in drug resistance. Future work 
may gauge the relative importance of AURKA in respect to other outputs of MYC in driving 
resistance to PI3K inhibitors. Our findings reveal that the combination of Aurora kinase 
inhibitors and PI3K-pathway inhibitors is synergistic and could be a promising clinical strategy 
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to enhance the treatment response in breast cancer. As single-agent responses to both PI3K-
pathway and Aurora kinase inhibitors have been modest, these findings may unlock the full 
potential of these agents in realizing a clinical benefit. 
 
Second, we used single-cell transcriptomics data and pharmacogenomic modeling as a way to 
inform upfront drug combinations based on systematic analysis of tumor subpopulation 
architectures.  Our data identified a recurrent subpopulation of cells in an ISG-state that was 
specific to TNBC cells and displayed heightened STING-pathway activation and genomic 
instability. By applying our MODRx approach we determined these cells are associated with 
chemoresistance and poor outcome in TNBC patients, but can be targeted using CDK4/6 or 
mTOR inhibitors. Our study potentially explains the cellular source of heightened ISG 
expression found in residual TNBC tumors after chemotherapy and calls for future work 
exploring the underlying mechanisms and clinical utility of targeting pre-existing chemoresistant 
ISG-subpopulations in TNBC. Using in silico and experimental approaches, our study provides 
an effective new framework to discover drug combinations capable of counteracting intrinsic cell 
variability by predicting drug responses of single cells within tumor cell subpopulations and 
systematically links transcriptional heterogeneity with drug actionability to optimize therapy 
combinations. Ongoing efforts are currently underway to translate this approach at scale by 
developing a machine-learning model for generating a drug-by-cell matrix to provide a 
systematic method for predicting single-cell responses and inform candidate combination 
strategies. 
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which we validated as an effective strategy for targeting this chemoresistant subpopulation in 
TNBC. Guided by our in silico modeling and single-cell predictions, we show the addition of 
palbociclib to gemcitabine or doxorubicin treatment is an effective strategy for increasing 
therapeutic efficacy on TNBC tumor landscapes in their entirety.  
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